{
    "01P.F": {
        "short_name": "MEDPACE HOLDINGS  DL-,01",
        "long_name": "Medpace Holdings, Inc.",
        "summary": "Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cincinnati"
    },
    "0L8.F": {
        "short_name": "LANTHEUS HLDGS  DL-,01",
        "long_name": "Lantheus Holdings, Inc.",
        "summary": "Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201 for use in MPI studies to detect cardiovascular disease; Gallium Ga 67 to detect various infections and cancerous tumors; and Quadramet, a therapeutic product. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment of neuroendocrine tumors. It serves radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic collaborations with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting R&D on PD-L1 immuno-oncology treatments; Insightec Ltd. for the treatment of glioblastoma and neurodegenerative conditions; and POINT Biopharma, Inc. to treat metastatic castration resistant prostate cancer. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "North Billerica"
    },
    "0ME.F": {
        "short_name": "TWIST BIOSCIENCEDL-,00001",
        "long_name": "Twist Bioscience Corporation",
        "summary": "Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "0YX.F": {
        "short_name": "SYSMEX CORP.",
        "long_name": "Sysmex Corporation",
        "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Kobe"
    },
    "1763.HK": {
        "short_name": "CIRC",
        "long_name": "China Isotope & Radiation Corporation",
        "summary": "China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through four segments: Pharmaceuticals, Radioactive Source Products, Irradiation, and Independent Clinical Laboratory Services and Other Businesses. The company's Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. Its Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The company's Irradiation segment offers irradiation service to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities to irradiation service providers. Its Independent Clinical Laboratory Services and Other Businesses segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. As of December 31, 2019, the company's sales network included 11,000 hospitals and other medical institutions, such as 1,800 tertiary hospitals, 5,000 secondary hospitals, and 4,400 primary hospitals in China. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Beijing"
    },
    "1B1.SI": {
        "short_name": "$ HC Surgical",
        "long_name": "HC Surgical Specialists Limited",
        "summary": "HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. It offers endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics. The company also offers treatment services for other conditions, such as haemorrhoids, anal abscesses, anal fissures, anal fistula, gallstones and inflammation of the gallbladder, hernias, gastric cancer, colorectal cancer, stomach cancer, colonic diverticular disease, and cysts and lipomas; and vein laser vascular, laparoscopy, and other general and specialized medical services. In addition, it provides home care, such as medical, nursing, physiotherapy, speech therapy, occupational therapy, and ambulance services; and general consultation and diagnostic services, including blood tests, X-Rays, ultrasound, CT Scans, and MRIs. The company operates 16 clinics in Singapore. HC Surgical Specialists Limited was incorporated in 2015 and is based in Singapore.",
        "currency": "SGD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SES",
        "market": "sg_market",
        "country": "Singapore",
        "city": "Singapore"
    },
    "1K9.F": {
        "short_name": "CAREDX INC.  DL-,001",
        "long_name": "CareDx, Inc",
        "summary": "CareDx, Inc. discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss, as well as a partnership with IDbyDNA, Inc. for the development of metagenomic infectious disease testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "1R3.F": {
        "short_name": "IZOTROPIC CORP.",
        "long_name": "Izotropic Corporation",
        "summary": "Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3D breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Surrey"
    },
    "20B.F": {
        "short_name": "BIOMARK DIAGNOSTICS INC.",
        "long_name": "Biomark Diagnostics Inc",
        "summary": "Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a collaboration with the University of Maryland School of Medicine related to the discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "2309.T": {
        "short_name": "CMIC HLDGS CO LTD",
        "long_name": "CMIC HOLDINGS Co., Ltd.",
        "summary": "CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model. It offers clinical trial services, including clinical operations and trials, data management, in-country clinical caretaker services, medical writing, patient recruitment, pharmacovigilance, project management, quality assurance, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry / out-licensing, medical devices and in vitro diagnostic, medical writing, national health insurance pricing, and product life cycle management consulting services. The company also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, technology transfer, as well as formulation, process, and analytical development services; and laboratory services, such as bioanalysis and GLP analysis, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, it offers patient and healthcare services, such as drug adherence support program, harmo, Helc+, prescription drug database, and selcheck, as well as call center, medical affairs, and marketing authorization holder related services; and health economics and outcome research, post-marketing surveillance, regulatory affairs consulting, regulatory submissions and correspondence, clinical research coordinating, clinical site administration, and site management services. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "2359.HK": {
        "short_name": "WUXI APPTEC",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd. provides research and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through, China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CMO/CDMO Services, and Other segments. It offers pharmaceutical discovery services across the drug discovery process; laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CMO/CDMO services; and administrative services, as well as sells scrap materials. The company was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "2397.T": {
        "short_name": "DNA CHIP RESEARCH INC",
        "long_name": "DNA Chip Research Inc.",
        "summary": "DNA Chip Research Inc. engages in the development of DNA microarrays in Japan. The company is involved in the research and development activities to investigate genetic information and develop tools and services for daily practical usage. Its products include Tbone EX Kit that is used by Japanese forensic laboratories in police force and universities; and Hyb-teacher, a DNA chip kit for Aldehyde dehydrogenase genotyping. The company also provides contract research services, including a range of analytical services from DNA chips to sequencings; and consultation on experimental planning, sample preparation, statistical analysis, and manuscript preparation to researchers; and diagnostic support services. DNA Chip Research Inc. was founded in 1999 and is based in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "2O9.F": {
        "short_name": "RENALYTIX AI PLC LS-,0025",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "2P4.F": {
        "short_name": "BIOPORTO A/S B  DK 1",
        "long_name": "BioPorto A/S",
        "summary": "BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric test that measures NGAL that is used on clinical chemical analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for human use, as well as used in research and clinical practice; and MBL ELISA kit, which is based on MBL antibodies. It also provides monoclonal antibodies that cover various research disciplines, such as microbiology, immune deficiency, renal, peptide hormones, and plasma proteins. In addition, the company offers antigens, such as human monoclonal IgE. Further, it provides lateral flow platform gRAD for the development of assays. The company sells its products through own sales team, distributors, and OEM partnerships. BioPorto A/S was founded in 2000 and is headquartered in Hellerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "2Y3.F": {
        "short_name": "BIONANO GENOMICS DL-,0001",
        "long_name": "Bionano Genomics, Inc.",
        "summary": "Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "300347.SZ": {
        "short_name": "HANGZHOU TIGERMED",
        "long_name": "Hangzhou Tigermed Consulting Co.,Ltd",
        "summary": "Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization in China and internationally. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting; clinical services in the areas of medical science, early clinical development, late phase development, medical monitoring, project management, patient recruitment, and quality management system; and biometrics services covering data management, biostatistics, and statistical programming. It also provides integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital; medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, IVD, GMP certificate, EU MDR and IVDR preparation, and value added services; and post-marketing study, real world evidence, and vaccine clinical trial services. The company was founded in 2004 and is based in Hangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Hangzhou"
    },
    "300396.SZ": {
        "short_name": "DIRUI INDUSTRIAL C",
        "long_name": "Dirui Industrial Co.,Ltd.",
        "summary": "Dirui Industrial Co.,Ltd. engages in the research and development, production, and sale of medical inspection products in the People's Republic of China. The company provides medical instruments, diagnostic reagents, test strips, etc. It offers biochemical blood cell, urine, coagulation, chemiluminescence immunoassay, and gynecological secretion analyzers. The company was founded in 1992 and is headquartered in Changchun, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Changchun"
    },
    "300463.SZ": {
        "short_name": "MACCURA BIOTECHNOL",
        "long_name": "Maccura Biotechnology Co.Ltd",
        "summary": "Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It also provides POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR and NGS; and pathology products. The company was founded in 1994 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Chengdu"
    },
    "300685.SZ": {
        "short_name": "AMOY DIAGNOSTICS C",
        "long_name": "Amoy Diagnostics Co., Ltd.",
        "summary": "Amoy Diagnostics Co., Ltd., a biotech company, develops and commercializes cancer diagnostics in China and internationally. The company offers molecular diagnostic kits, including EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits for oncology precision medicine; and NGS, real-time PCR, FISH, and extraction assays. The company has a strategic partnership agreement with Loxo Oncology, Inc. Amoy Diagnostics Co., Ltd. Was founded in 2008 and is based in Xiamen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Xiamen"
    },
    "34D.F": {
        "short_name": "DIASORIN S.P.A.  EO 1",
        "long_name": "DiaSorin S.p.A.",
        "summary": "DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Italy",
        "city": "Saluggia"
    },
    "39K.F": {
        "short_name": "CENTOGENE N.V. EO -,12",
        "long_name": "Centogene N.V.",
        "summary": "Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Rostock"
    },
    "39K.MU": {
        "short_name": "CENTOGENE N.V. EO -,12",
        "long_name": "Centogene N.V.",
        "summary": "Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "Germany",
        "city": "Rostock"
    },
    "3D0A.F": {
        "short_name": "TELO GENOMICS CORP. O.N.",
        "long_name": "Telo Genomics Corp.",
        "summary": "Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "3DC.SG": {
        "short_name": "Cordlife Group Ltd Registered S",
        "long_name": "Cordlife Group Limited",
        "summary": "Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, Macau, India, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines, Bangladesh, and internationally. It operates through two segments, Banking and Diagnostics. The company provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening, and family genetic screening services. It also offers management, marketing, and property investment services. The company was formerly known as Cordlife Pte Ltd and changed its name to Cordlife Group Limited in 2011. Cordlife Group Limited was founded in 2001 and is headquartered in Singapore.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Singapore",
        "city": "Singapore"
    },
    "3T2.F": {
        "short_name": "T2 BIOSYSTEMS  DL-,001",
        "long_name": "T2 Biosystems, Inc.",
        "summary": "T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lexington"
    },
    "45E.F": {
        "short_name": "NATERA INC.  DL-,0001",
        "long_name": "Natera, Inc.",
        "summary": "Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Carlos"
    },
    "45Z.F": {
        "short_name": "POL.BANK KOMOR.MAC. ZY-,5",
        "long_name": "Polski Bank Kom\u00f3rek Macierzystych S.A.",
        "summary": "Polski Bank Kom\u00c3\u00b3rek Macierzystych S.A. operates an umbilical cord blood bank. It operates through B2C, B2B, and R&D segments. The company provides diagnostic services; operates one day hospital and a cell and tissue bank. It also manages diagnostic laboratory and ultrasound diagnostics sites; operates web portal and provides marketing activities; and conducts research activities. The company offers its services in Serbia, Sweden, Ukraine, Lithuania, and the United Kingdom, as well as various Balkan countries and Egypt. Polski Bank Kom\u00c3\u00b3rek Macierzystych S.A. was incorporated in 2003 and is based in Warsaw, Poland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Poland",
        "city": "Warsaw"
    },
    "4671.T": {
        "short_name": "FALCO HOLDINGS CO LTD",
        "long_name": "FALCO HOLDINGS Co., Ltd.",
        "summary": "FALCO HOLDINGS Co., Ltd., a medical service company, primarily provides clinical testing and dispensing pharmacy services to medical institutions and companies in Japan. It offers clinical testing services in the fields of genetic tests, biochemistry, hematology, pathology, immunology, microbiology, and radio immunoassay; genetic testing services; and genomic-based drug discovery and biotechnology drug development services. The company also provides medical information technology services; food sanitation and environmental testing services; and food related genetic testing services to food manufacturers, retailers, and restaurants. In addition, it is involved in the dispensing pharmacies and drugstores business; and development and sale of various medical information systems, including @home Dr. electronic medical charts for clinics with concentrated clinical testing, as well as TASCAL for ASP, a medical support system. The company was founded in 1962 and is headquartered in Kyoto, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Kyoto"
    },
    "4694.T": {
        "short_name": "BML INC",
        "long_name": "BML, Inc.",
        "summary": "BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis; microbiological tests for medical and pharmaceutical societies and organizations; and laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies. It also develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, and subsequent test procedures; and provides electronic medical charts for networking medical information, as well as offers preventive medicine services. In addition, the company provides food sanitation control and food processing services comprising contract services for microorganism testing of raw materials, and prepared and processed foods; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and waste water tests; work sanitation management services, such as measurement of ethylene oxide gas, formaldehyde, organic solvents, and dust; environmental monitoring services, including measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal diseases; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. BML, Inc. was founded in 1955 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "505.SI": {
        "short_name": "$ AsiaMedic",
        "long_name": "AsiaMedic Limited",
        "summary": "AsiaMedic Limited, an investment holding company, provides healthcare services in Singapore. It focuses on the management of clinical services in the fields of disease prevention, early illness detection, medical imaging, and medical aesthetics. The company offers health risk assessments and screenings, and anti-aging and health risk management programs for optimized healthy aging and wellness. It also provides general and sub-specialty computerised tomography (CT) and magnetic resonance imaging (MRI) imaging, such as cardiovascular, neuro radiological, ENT, and musculoskeletal, as well as positron emission tomography (PET)/CT imaging for diagnosis, staging, localization, and monitoring progress of cancer and cardiac diseases; and other imaging services, including mammography, bone densitometry, ultrasound, and X-ray. In addition, the company operates travel clinics and family medicine practices; and provides medical aesthetic services, as well as sells aesthetic related products. AsiaMedic Limited was incorporated in 1974 and is based in Singapore.",
        "currency": "SGD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SES",
        "market": "sg_market",
        "country": "Singapore",
        "city": "Singapore"
    },
    "603108.SS": {
        "short_name": "SHANGHAI RUNDA MEDICAL TECHNOLO",
        "long_name": "Shanghai Runda Medical Technology Co., Ltd.",
        "summary": "Shanghai Runda Medical Technology Co., Ltd. provides integrated medical laboratory services in China. It offers platform supply, laboratory design/renovation, laboratory standardization, and information management system services; medical solutions to help healthcare professionals in the areas of biochemistry, diabetes, POCT, immunoassay analyzer, and molecular biology diagnosis; professional technical services; and logistic services. The company was founded in 1999 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Shanghai"
    },
    "603127.SS": {
        "short_name": "JOINN LABORATORIES (CHINA) CO L",
        "long_name": "Joinn Laboratories (China) Co.,Ltd.",
        "summary": "Joinn Laboratories (China) Co., Ltd. provides preclinical and non-clinical services. It evaluates various drugs, including biologics, pharmaceutical chemicals, and plant medicines for indications, such as renal and metabolic diseases, cardiology and hematology diseases, COPD, ophthalmics and oncology, and immune-related diseases. The company's services include screening services, such as efficiency screening, bioavailability, ADME screening, and non-GLP toxicology studies; pre-clinical safety assessment comprising general toxicology, safety pharmacology, developmental and reproductive toxicology, genetic and ocular toxicology, clinical pathology, analytical and bioanalytical analysis, immunology, and biomarker assays; pharmacodynamics services; and services to evaluate and optimize the absorption, distribution, metabolism, and elimination (ADME), as well as pharmacokinetic properties of potential drugs from early discovery projects. Its services also comprise clinical trials services to support Phase I to Phase IV studies and deep therapeutic clinical trial services; a range of safety assessment services for medical devices, chemicals, and agrochemicals; regulatory consulting services in the areas of pharmaceuticals, biologics, Chinese medicine, medical devices, veterinary medicines, and agrochemicals; and food animal evaluation services comprising candidate selection, efficacy, and safety evaluation studies on animals' health products, animal remedies, and fodders. In addition, the company offers traditional animals, such as outbred rats, inbred strain mice, outbred mice, and immunodeficient mice. It serves pharmaceutical, medical device, chemical, biotechnology, and agricultural development companies, as well as regulatory and other government agencies. The company operates in approximately 30 provinces in China; and in Europe, North America, Southeast Asia, and Australia. Joinn Laboratories (China) Co., Ltd. was founded in 1995 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "603259.SS": {
        "short_name": "WUXI APPTEC CO LTD",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd. provides research and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through, China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CMO/CDMO Services, and Other segments. It offers pharmaceutical discovery services across the drug discovery process; laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CMO/CDMO services; and administrative services, as well as sells scrap materials. The company was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Shanghai"
    },
    "603658.SS": {
        "short_name": "AUTOBIO DIAGNOSTICS CO LTD",
        "long_name": "Autobio Diagnostics Co., Ltd.",
        "summary": "Autobio Diagnostics Co., Ltd. engages in the research and development, production, and distribution of clinical diagnostic products in China and internationally. It develops immunoassay, biochemistry, microbiology, and IVD reagents; and instruments, such as automation and semi-automation systems, as well as medical laboratory solutions. The company's immunoassay products AutoLumo A2000 Plus, an automatic Chemiluminescence immunoassay analyzer; automatic microplate chemiluminescent enzyme immunoassay; and LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Its microbiology products comprise automated mass spectrometry microbial identification systems, automated blood culture systems; and blood culture bottles, AUTOMIC strips, and mycoplasma IES. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is based in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Auto Industrial Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Zhengzhou"
    },
    "603716.SS": {
        "short_name": "THALYS MEDICAL TECHNOLOGY GROUP",
        "long_name": "Thalys Medical Technology Group Inc.",
        "summary": "Thalys Medical Technology Group Inc. engages in the medical intensive business and operation services in China. The company was formerly known as Thalys Medical Technology Inc. and changed its name to Thalys Medical Technology Group Inc. in September 2020. Thalys Medical Technology Group Inc. was founded in 2004 and is headquartered in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Wuhan"
    },
    "603882.SS": {
        "short_name": "GUANGZHOU KINGMED DIAGNOSTICS G",
        "long_name": "Guangzhou Kingmed Diagnostics Group Co., Ltd.",
        "summary": "Guangzhou Kingmed Diagnostics Group Co., Ltd. operates as a third-party medical laboratory company in China. The company offers medical examination, clinical trial, food and hygiene testing, and scientific research services. As of January 3, 2019, it operated 37 testing laboratories with approximately 2,400 testing items to serve approximately 21,000 medical institutions. The company has a strategic partnership with Personal Genome Diagnostics Inc. to serve the clinical trial screening needs of pharmaceutical partners in the Asian market. The company was founded in 1994 and is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Guangzhou"
    },
    "63V.F": {
        "short_name": "VERICI DX PLC  LS-,001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Penarth"
    },
    "6502.F": {
        "short_name": "OPGEN INC.  DL-,01",
        "long_name": "OpGen, Inc.",
        "summary": "OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "65HA.F": {
        "short_name": "HTG MOLECUL.DIAGN.DL-,001",
        "long_name": "HTG Molecular Diagnostics, Inc.",
        "summary": "HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Tucson"
    },
    "6869.T": {
        "short_name": "SYSMEX CORP",
        "long_name": "Sysmex Corporation",
        "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Kobe"
    },
    "6CB.F": {
        "short_name": "GLOBAL CORD BLOOD DL-0001",
        "long_name": "Global Cord Blood Corporation",
        "summary": "Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2020, it had three operating cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Hong Kong",
        "city": "Central"
    },
    "6XC1.F": {
        "short_name": "SOLENO THERAPEUT. DL-,001",
        "long_name": "Soleno Therapeutics, Inc.",
        "summary": "Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "7F0.F": {
        "short_name": "FULGENT GENETICS DL-,0001",
        "long_name": "Fulgent Genetics, Inc.",
        "summary": "Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home Covid-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Temple City"
    },
    "80R.F": {
        "short_name": "AROCELL AB",
        "long_name": "AroCell AB (publ)",
        "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Uppsala"
    },
    "8IN.F": {
        "short_name": "SYNEOS HEALTH A  DL-,01",
        "long_name": "Syneos Health, Inc.",
        "summary": "Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications solutions, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic agreement with Daiichi Sankyo, Inc. for the development of Daiichi Sankyo'S Adc oncology pipeline; and a partnership with VBI Vaccines Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "8VP1.F": {
        "short_name": "AVRICORE HEALTH INC.",
        "long_name": "Avricore Health Inc.",
        "summary": "Avricore Health Inc. operates as a healthcare technology company in Canada. The company provides HealthTab, a lab-accurate point of care testing platform. In addition, it offers Corozon Platform, which consists of Corozon Academy that provides practical professional education to community pharmacists; and Corozon Hardware, an e-commerce portal that allows pharmacists to order point-of-care diagnostic devices and supplies. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "8XB.F": {
        "short_name": "BIOCARTIS GR. 144A/REG S",
        "long_name": "Biocartis Group NV",
        "summary": "Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca's pharmaceutical products; Bristol-Myers Squibb Company for the registration of Idylla MSI Test as companion diagnostic test for metastatic colorectal cancer in China; and Endpoint Health, Inc. for the development and commercialization of a novel companion diagnostic test based on Idylla molecular diagnostics platform. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "9CX.MU": {
        "short_name": "CELL MEDXCORP.  DL -,001",
        "long_name": "Cell MedX Corp.",
        "summary": "Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general relaxation and for the temporary relief of pain due to sore and/or aching muscles. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "Carson City"
    },
    "A": {
        "short_name": "Agilent Technologies, Inc.",
        "long_name": "Agilent Technologies, Inc.",
        "summary": "Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Santa Clara"
    },
    "AALR3.SA": {
        "short_name": "ALLIAR      ON      NM",
        "long_name": "Centro de Imagem Diagn\u00f3sticos S.A.",
        "summary": "Centro de Imagem Diagn\u00c3\u00b3sticos S.A. provides diagnostic medicine services in Brazil. Its diagnostic imaging services include imaging diagnosis and chart-based diagnosis; nuclear medicine and cytology; pathological anatomy; and clinical tests. The company also engages in the provision of health consulting, advisory, courses and lectures, and the services related to health; management of chronic diseases; scientific and technologic research and development related to diagnostic medicine; preparation, issue, publication, and distribution of newspapers, books, magazines, periodicals, and other media for the dissemination of scientific knowledge; and grant and management of business franchises. Centro de Imagem Diagn\u00c3\u00b3sticos S.A. was founded in 1992 and is headquartered in S\u00c3\u00a3o Paulo, Brazil.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "Brazil",
        "city": "S\u00c3\u00a3o Paulo"
    },
    "ABDX.L": {
        "short_name": "ABINGDON HEALTH PLC ORD 0.025P",
        "long_name": "Abingdon Health Plc",
        "summary": "Abingdon Health Plc, a technology-enabled lateral flow diagnostics company, develops, manufactures, and markets medical diagnostics worldwide. The company offers AbC-19 Rapid Test, a COVID-19 neutralizing antibody test; nucleic acid lateral flow immunoassays; and Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. It also provides lateral flow development, manufacturing, and reader customization services. The company was founded in 2008 and is headquartered in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "ABMC": {
        "short_name": "AMERICAN BIO MEDICA CORP",
        "long_name": "American Bio Medica Corporation",
        "summary": "American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides bulk test strip contract manufacturing services to non-affiliated diagnostic companies. American Bio Medica Corporation serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets in the United States and internationally. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was founded in 1986 and is based in Kinderhook, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Kinderhook"
    },
    "AGHC": {
        "short_name": "AEON GLOBAL HEALTH CORP",
        "long_name": "Aeon Global Health Corp.",
        "summary": "Aeon Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through Laboratory Testing Services and Web-Based Software segments. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, as well as compliance with regulatory requirements. The company was formerly known as Authentidate Holding Corp. and changed its name to Aeon Global Health Corp. in January 2018. Aeon Global Health Corp. is headquartered in Gainesville, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Gainesville"
    },
    "AGL.L": {
        "short_name": "ANGLE PLC ORD 10P",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "AKU": {
        "short_name": "Akumin Inc.",
        "long_name": "Akumin Inc.",
        "summary": "Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2019, the company operated 129 imaging centers located in Florida, Pennsylvania, Delaware, Georgia, Texas, Illinois, and Kansas. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, and other diagnostic or interventional radiology procedures; and online medical bill payment services. Akumin Inc. is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "AKU.TO": {
        "short_name": "AKUMIN INC",
        "long_name": "Akumin Inc.",
        "summary": "Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2019, the company operated 129 imaging centers located in Florida, Pennsylvania, Delaware, Georgia, Texas, Illinois, and Kansas. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, and other diagnostic or interventional radiology procedures; and online medical bill payment services. Akumin Inc. is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "ALBIO.PA": {
        "short_name": "BIOSYNEX",
        "long_name": "Biosynex SA",
        "summary": "Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. It offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as instruments. The company also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper-and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "ALERS.PA": {
        "short_name": "EUROBIO-SCIENTIFIC",
        "long_name": "Eurobio Scientific Soci\u00e9t\u00e9 anonyme",
        "summary": "Eurobio Scientific Soci\u00c3\u00a9t\u00c3\u00a9 anonyme discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in emergency clinics for the determination of the tetanus vaccination status of a patient; and commercializes cell culture media, molecular biology reagents, and proprietary antibodies. Its in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; and licensed products comprise AlloMap, a gene-expression profiling based blood test for the surveillance of heart-transplant patients. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in June 2018. Eurobio Scientific Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1997 and is headquartered in Les Ulis, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Les Ulis"
    },
    "ALLPF": {
        "short_name": "AROCELL AB",
        "long_name": "AroCell AB (publ)",
        "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Sweden",
        "city": "Uppsala"
    },
    "ALMDT.PA": {
        "short_name": "MEDIANTECHNOLOGIES",
        "long_name": "Median Technologies SA",
        "summary": "Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiopsy (Imaging BIOmarker Phenotyping System), a phenomics imaging platform empower translational research with AI powered Biomarker identification tools and inform clinical decisions using CT scan similarity search for patient profiling services; and iSee for image analysis and management in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. The company was founded in 2002 and is based in Valbonne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Valbonne"
    },
    "ALNOV.PA": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "ALPRE.PA": {
        "short_name": "PREDILIFE",
        "long_name": "Predilife S.A.",
        "summary": "Predilife S.A. develops and sells medical techniques and mathematical models. The company provides genetic testing, medical imaging, etc. Its product, MammoRisk, is a test for predicting the development of breast cancer based on the patient's individual risk. The company has a partnership agreement with Institut Curie for genetic analyses for MammoRisk. Predilife S.A. was founded in 2004 and is based in Villejuif, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Villejuif"
    },
    "AMCY": {
        "short_name": "ACS GLOBAL INC",
        "long_name": "ACS Global, Inc.",
        "summary": "ACS Global, Inc. engages in the collection, processing, and long-term storage of stem cells. The company's services would allow individuals to privately preserve their stem cells for potential future use in cell therapy. The company was formerly known as American CryoStem Corp. and changed its name to ACS Global, Inc. in June 2011. The company is based in Red Bank, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Red Bank"
    },
    "ANIX": {
        "short_name": "Anixa Biosciences, Inc.",
        "long_name": "Anixa Biosciences, Inc.",
        "summary": "Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Jose"
    },
    "ANPCY": {
        "short_name": "ANGLE",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "ARA": {
        "short_name": "American Renal Associates Holdi",
        "long_name": "American Renal Associates Holdings, Inc.",
        "summary": "American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Beverly"
    },
    "AROC.ST": {
        "short_name": "AroCell AB (publ)",
        "long_name": "AroCell AB (publ)",
        "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Uppsala"
    },
    "ARYC": {
        "short_name": "ARRAYIT CORP",
        "long_name": "Arrayit Corporation",
        "summary": "Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Sunnyvale"
    },
    "AVCR.V": {
        "short_name": "AVRICORE HEALTH INC",
        "long_name": "Avricore Health Inc.",
        "summary": "Avricore Health Inc. operates as a healthcare technology company in Canada. The company provides HealthTab, a lab-accurate point of care testing platform. In addition, it offers Corozon Platform, which consists of Corozon Academy that provides practical professional education to community pharmacists; and Corozon Hardware, an e-commerce portal that allows pharmacists to order point-of-care diagnostic devices and supplies. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "AVCRF": {
        "short_name": "AVRICORE HEALTH INC",
        "long_name": "Avricore Health Inc.",
        "summary": "Avricore Health Inc. operates as a healthcare technology company in Canada. The company provides HealthTab, a lab-accurate point of care testing platform. In addition, it offers Corozon Platform, which consists of Corozon Academy that provides practical professional education to community pharmacists; and Corozon Hardware, an e-commerce portal that allows pharmacists to order point-of-care diagnostic devices and supplies. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "AWH": {
        "short_name": "Aspira Women's Health Inc.",
        "long_name": "Aspira Women's Health Inc.",
        "summary": "Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. Aspira Women's Health Inc. has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test. It serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "AXDX": {
        "short_name": "Accelerate Diagnostics, Inc.",
        "long_name": "Accelerate Diagnostics, Inc.",
        "summary": "Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Tucson"
    },
    "AXDX.MX": {
        "short_name": "ACCELERATE DIAGNOSTICS INC",
        "long_name": "Accelerate Diagnostics, Inc.",
        "summary": "Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Tucson"
    },
    "B003.F": {
        "short_name": "BIOCEPT INC.  DL -,0001",
        "long_name": "Biocept, Inc.",
        "summary": "Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "BASI": {
        "short_name": "Bioanalytical Systems, Inc.",
        "long_name": "Bioanalytical Systems, Inc.",
        "summary": "Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "West Lafayette"
    },
    "BCART.BR": {
        "short_name": "BIOCARTIS",
        "long_name": "Biocartis Group NV",
        "summary": "Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca's pharmaceutical products; Bristol-Myers Squibb Company for the registration of Idylla MSI Test as companion diagnostic test for metastatic colorectal cancer in China; and Endpoint Health, Inc. for the development and commercialization of a novel companion diagnostic test based on Idylla molecular diagnostics platform. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "BD1.AX": {
        "short_name": "BARD1 LIFE FPO",
        "long_name": "BARD1 Life Sciences Limited",
        "summary": "BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "South Perth"
    },
    "BDSX": {
        "short_name": "Biodesix, Inc.",
        "long_name": "Biodesix, Inc.",
        "summary": "Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Boulder"
    },
    "BEAT": {
        "short_name": "BioTelemetry, Inc.",
        "long_name": "BioTelemetry, Inc.",
        "summary": "BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Malvern"
    },
    "BGLC": {
        "short_name": "BIONEXUS GENE LAB CORP",
        "long_name": "BioNexus Gene Lab Corporation",
        "summary": "BioNexus Gene Lab Corporation, a molecular diagnostics company, develops and commercializes molecular diagnostic tests for the early detection of diseases and personalized health management, primarily focusing on cardiovascular, diabetes, and cancer-related indications primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of cancers, including nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon; bowel diseases, such as colitis and Crohn; and osteoarthritis. The company markets its blood screening process to health care providers, such as doctors, laboratories, and hospitals. BioNexus Gene Lab Corporation was founded in 2017 and is based in Kuala Lumpur, Malaysia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Malaysia",
        "city": "Kuala Lumpur"
    },
    "BIOC": {
        "short_name": "Biocept, Inc.",
        "long_name": "Biocept, Inc.",
        "summary": "Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "BIOPOR.CO": {
        "short_name": "BioPorto A/S",
        "long_name": "BioPorto A/S",
        "summary": "BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric test that measures NGAL that is used on clinical chemical analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for human use, as well as used in research and clinical practice; and MBL ELISA kit, which is based on MBL antibodies. It also provides monoclonal antibodies that cover various research disciplines, such as microbiology, immune deficiency, renal, peptide hormones, and plasma proteins. In addition, the company offers antigens, such as human monoclonal IgE. Further, it provides lateral flow platform gRAD for the development of assays. The company sells its products through own sales team, distributors, and OEM partnerships. BioPorto A/S was founded in 2000 and is headquartered in Hellerup, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BIOQ": {
        "short_name": "BIOQUAL INC",
        "long_name": "Bioqual, Inc.",
        "summary": "Bioqual, Inc. provides research, development, pre-clinical, and testing/assay services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides in-vivo animal model services related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "BMGP": {
        "short_name": "BIOMAGNETICS DIAGNOSTICS CORP",
        "long_name": "Biomagnetics Diagnostics Corp.",
        "summary": "Biomagnetics Diagnostics Corporation, a medical device and biotechnology company, designs, patents, and markets diagnostic equipment and immunoassays, and other biotechnologies. Its products include High Throughput Screening\u00c2\u0096Magnetic Testing Platform (HTS-MTP) to provide qualitative and quantitative results from a single test by detecting the target virus through measuring the magnetic field of micro-particles bonded to the virus in a fraction of the time; and Integrated Optical Biosensor System that is based on protein-receptor binding, which brings two or more optically tagged receptors into close proximity using planar optical waveguides, and triggers fluorescence changes identified by tiny on-board detectors. Biomagnetics Diagnostics Corporation has a licensing and collaborative research and development agreement with Las Alamos National Security LLC for Integrated Optical BioSensor. The company was founded in 1997 and is based in Orangevale, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Orangevale"
    },
    "BMKDF": {
        "short_name": "BIOMARK DIAGNOSTICS INC",
        "long_name": "Biomark Diagnostics Inc",
        "summary": "Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a collaboration with the University of Maryland School of Medicine related to the discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "BMRA": {
        "short_name": "Biomerica, Inc.",
        "long_name": "Biomerica, Inc.",
        "summary": "Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Irvine"
    },
    "BMXMF": {
        "short_name": "BIOMERIEUX",
        "long_name": "bioM\u00e9rieux S.A.",
        "summary": "bioM\u00c3\u00a9rieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D M\u00c3\u00a9rieux. bioM\u00c3\u00a9rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioM\u00c3\u00a9rieux S.A. is a subsidiary of Institut M\u00c3\u00a9rieux SA.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Marcy l'\u00c3\u0089toile"
    },
    "BMZ.MU": {
        "short_name": "BML INC.",
        "long_name": "BML, Inc.",
        "summary": "BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis; microbiological tests for medical and pharmaceutical societies and organizations; and laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies. It also develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, and subsequent test procedures; and provides electronic medical charts for networking medical information, as well as offers preventive medicine services. In addition, the company provides food sanitation control and food processing services comprising contract services for microorganism testing of raw materials, and prepared and processed foods; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and waste water tests; work sanitation management services, such as measurement of ethylene oxide gas, formaldehyde, organic solvents, and dust; environmental monitoring services, including measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal diseases; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. BML, Inc. was founded in 1955 and is headquartered in Tokyo, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "BNGO": {
        "short_name": "Bionano Genomics, Inc.",
        "long_name": "Bionano Genomics, Inc.",
        "summary": "Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "BNR": {
        "short_name": "Burning Rock Biotech Limited",
        "long_name": "Burning Rock Biotech Limited",
        "summary": "Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 13 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen Plus that targets therapy and immunotherapy, as well as immunotherapy- related biomarkers, such as microsatellite instability and tumor mutation burden, and NTRK fusions; and LungPlasma, a circulating tumor DNA liquid biopsy- based test for non-small cell lung cancer. It also offers ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with major pharmaceutical companies, including AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone Pharmaceuticals, and BeiGene primarily through central laboratory and companion diagnostics development services to pharmaceutical companies. The company was founded in 2014 and is headquartered in Guangzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "city": "Guangzhou"
    },
    "BOUL.ST": {
        "short_name": "Boule Diagnostics AB",
        "long_name": "Boule Diagnostics AB (publ)",
        "summary": "Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. It provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning kits and plastic micro capillaries under the Swelab, Medonic, and Quintus brands; and veterinary clinical chemistry analyzer and diagnostics systems under the Exigo brand. The company sells its products directly in Sweden and the United States, as well as through distributors internationally. It serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and companies in blood diagnostics. The company has operations in Sweden, the United States, Mexico, and Russia. Boule Diagnostics AB (publ) was founded in 1956 and is headquartered in Sp\u00c3\u00a5nga, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Sp\u00c3\u00a5nga"
    },
    "BQB1.F": {
        "short_name": "YOURGENE HEALTH  LS 0,001",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "BRSYF": {
        "short_name": "BRAINSWAY LTD",
        "long_name": "Brainsway Ltd.",
        "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "BS5.F": {
        "short_name": "BIOANALYTICIAL SYS INC.",
        "long_name": "Bioanalytical Systems, Inc.",
        "summary": "Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "West Lafayette"
    },
    "BUX.CN": {
        "short_name": "BioMarkDiagnos",
        "long_name": "Biomark Diagnostics Inc",
        "summary": "Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a collaboration with the University of Maryland School of Medicine related to the discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "BWAY": {
        "short_name": "Brainsway Ltd.",
        "long_name": "Brainsway Ltd.",
        "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "BWAY.TA": {
        "short_name": "BRAINSWAY LTD",
        "long_name": "Brainsway Ltd.",
        "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "C97.F": {
        "short_name": "CO-DIAGNOSTICS DL-,001",
        "long_name": "Co-Diagnostics, Inc.",
        "summary": "Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "C97.MU": {
        "short_name": "CO-DIAGNOSTICS DL-,001",
        "long_name": "Co-Diagnostics, Inc.",
        "summary": "Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "CBAV.MC": {
        "short_name": "CLINICA BAVIERA S.A.",
        "long_name": "Cl\u00ednica Baviera, S.A.",
        "summary": "Cl\u00c3\u00adnica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmolog\u00c3\u00ada, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Madrid"
    },
    "CDNA": {
        "short_name": "CareDx, Inc.",
        "long_name": "CareDx, Inc",
        "summary": "CareDx, Inc. discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss, as well as a partnership with IDbyDNA, Inc. for the development of metagenomic infectious disease testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "CELC": {
        "short_name": "Celcuity Inc.",
        "long_name": "Celcuity Inc.",
        "summary": "Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It develops CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELsignia MP test to diagnose 11 cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Minneapolis"
    },
    "CEMI": {
        "short_name": "Chembio Diagnostics, Inc.",
        "long_name": "Chembio Diagnostics, Inc.",
        "summary": "Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Hauppauge"
    },
    "CGN.CN": {
        "short_name": "CognetivityNeu",
        "long_name": "Cognetivity Neurosciences Ltd.",
        "summary": "Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical and commercial environments for potentially allowing early diagnosis of dementia. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "CGNH": {
        "short_name": "CARDIOGENICS HOLDINGS INC",
        "long_name": "CardioGenics Holdings Inc",
        "summary": "CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "CGNSF": {
        "short_name": "COGNETIVITY NEUROSCIENCES LTD",
        "long_name": "Cognetivity Neurosciences Ltd.",
        "summary": "Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical and commercial environments for potentially allowing early diagnosis of dementia. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "CHEK": {
        "short_name": "Check-Cap Ltd.",
        "long_name": "Check-Cap Ltd.",
        "summary": "Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Isfiya"
    },
    "CHHL": {
        "short_name": "CHINA HOLDINGS INC",
        "long_name": "China Holdings, Inc.",
        "summary": "China Holdings, Inc., a development stage company, focuses to engage in the land and real estate development, energy, renewable energy, resources, utilities, and pharmaceutical businesses. The company, through its subsidiary, China Power, Inc., focuses on the mergers and acquisitions, investment, research and development, construction, and operation of energy, renewable energy, and environment protection projects, as well as develops renewable energy projects, pipelines in biomass energy projects, and hydropower plants in China and worldwide. China Holdings, Inc., through its another subsidiary, China Minerals Holdings, Inc., focuses to engage in the exploration, development, and production of precious and rare metals resource and properties, including vanadium, molybdenum, and uranium. In addition, the company, through its subsidiary, China Health Holdings, Inc., focuses on the development, manufacture, marketing, and distribution of pharmaceutical drugs and dietary supplements in China and worldwide. The company was formerly known as China Health Holding, Inc. and changed its name to China Holdings, Inc. in May 2007. China Holdings, Inc. was founded in 2002 and is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Las Vegas"
    },
    "CLIFF": {
        "short_name": "CORDLIFE GROUP LIMITED",
        "long_name": "Cordlife Group Limited",
        "summary": "Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, Macau, India, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines, Bangladesh, and internationally. It operates through two segments, Banking and Diagnostics. The company provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening, and family genetic screening services. It also offers management, marketing, and property investment services. The company was formerly known as Cordlife Pte Ltd and changed its name to Cordlife Group Limited in 2011. Cordlife Group Limited was founded in 2001 and is headquartered in Singapore.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Singapore",
        "city": "Singapore"
    },
    "CMXC": {
        "short_name": "CELL MEDX CORP",
        "long_name": "Cell MedX Corp.",
        "summary": "Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general relaxation and for the temporary relief of pain due to sore and/or aching muscles. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Carson City"
    },
    "CNTG": {
        "short_name": "Centogene N.V.",
        "long_name": "Centogene N.V.",
        "summary": "Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Germany",
        "city": "Rostock"
    },
    "CO": {
        "short_name": "Global Cord Blood Corporation",
        "long_name": "Global Cord Blood Corporation",
        "summary": "Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2020, it had three operating cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Hong Kong",
        "city": "Central"
    },
    "CODX": {
        "short_name": "Co-Diagnostics, Inc.",
        "long_name": "Co-Diagnostics, Inc.",
        "summary": "Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "CRL": {
        "short_name": "Charles River Laboratories Inte",
        "long_name": "Charles River Laboratories International, Inc.",
        "summary": "Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "CSTL": {
        "short_name": "Castle Biosciences, Inc.",
        "long_name": "Castle Biosciences, Inc.",
        "summary": "Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Friendswood"
    },
    "CTE.AX": {
        "short_name": "CRYOSITE FPO",
        "long_name": "Cryosite Limited",
        "summary": "Cryosite Limited engages in the supply chain logistics and management of pharmaceutical products used in clinical trials, and biological materials in Australia. It operates in two segments, Clinical Trials & Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials & Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, and biological storage services to the clinical trial and research industry. The Cord Blood and Tissues Storage segment offers long term storage for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. Cryosite Limited was founded in 1999 and is based in South Granville, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "South Granville"
    },
    "CYPS": {
        "short_name": "CYCLOPSS CORP",
        "long_name": "Cyclo3pss Corporation",
        "summary": "Cyclo3pss Corporation engages in the licensing, manufacture, sale, and installation of ozone food processing products; and ozone washing and laundry sorting and counting systems for commercial and institutional laundries. It also engages in the research and development of technologies for the sterilization and/or disinfection of certain consumer products. The company was founded in 1927 and is based in Salt Lake City, Utah. In July 2002, the Board of Directors of Cyclo3pss determined to suspend all operations of the company immediately due to an inability to locate willing investors and to secure necessary and suitable financing.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "D6M.F": {
        "short_name": "GENEDRIVE PLC  LS -,015",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "D9IA.SG": {
        "short_name": "Chembio Diagnostics Inc. Regist",
        "long_name": "Chembio Diagnostics, Inc.",
        "summary": "Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Hauppauge"
    },
    "D9Z.F": {
        "short_name": "CLINICA BAVIERA SA EO-,10",
        "long_name": "Cl\u00ednica Baviera, S.A.",
        "summary": "Cl\u00c3\u00adnica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmolog\u00c3\u00ada, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Spain",
        "city": "Madrid"
    },
    "DAP.DE": {
        "short_name": "DANAHER CORP.  DL-,01",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Washington"
    },
    "DAP.F": {
        "short_name": "DANAHER CORP.  DL-,01",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Washington"
    },
    "DASA3.SA": {
        "short_name": "DASA        ON",
        "long_name": "Diagn\u00f3sticos da Am\u00e9rica S.A.",
        "summary": "Diagn\u00c3\u00b3sticos da Am\u00c3\u00a9rica S.A. provides diagnostic test services in Latin America. It offers approximately 3,000 types of examinations of clinical analyses and diagnostic imaging services. The company also provides support services to approximately 5,000 laboratories under the Alvaro brand, as well as operates for the public sector under the Cient\u00c3\u00adficaLab brand. The company was formerly known as Laborat\u00c3\u00b3rio Cl\u00c3\u00adnico Delboni Auriemo S.A. and changed its name to Diagn\u00c3\u00b3sticos da Am\u00c3\u00a9rica S.A. in August 17, 2000. The company was founded in 1966 and is based in Barueri, Brazil. Diagn\u00c3\u00b3sticos da Am\u00c3\u00a9rica S.A. is a subsidiary of Cromossomo Participa\u00c3\u00a7\u00c3\u00b5es II S.A.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "Brazil",
        "city": "Barueri"
    },
    "DC4.F": {
        "short_name": "DEXCOM INC.  DL-,001",
        "long_name": "DexCom, Inc.",
        "summary": "DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; a collaboration with Companion Medical, Inc.; and a development and commercialization agreement with Tandem Diabetes Care, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "DGNS.JK": {
        "short_name": "Diagnos Laboratorium Utama Tbk.",
        "long_name": "PT Diagnos Laboratorium Utama Tbk",
        "summary": "PT Diagnos Laboratorium Utama Tbk provides health services using laboratories. It offers clinical and genomics laboratory, inspection package, homecare diagnosis, SARS-COV-2 examination package, and examination panel services. The company was founded in 2007 and is headquartered in Central Jakarta, Indonesia.",
        "currency": "IDR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "JKT",
        "market": "id_market",
        "country": "Indonesia",
        "city": "Central Jakarta"
    },
    "DGX": {
        "short_name": "Quest Diagnostics Incorporated",
        "long_name": "Quest Diagnostics Incorporated",
        "summary": "Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated has a strategic collaboration with hc1; and strategic relationships with Clinical Genomics Pty Ltd and Anthem Inc. The company was founded in 1967 and is headquartered in Secaucus, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Secaucus"
    },
    "DHER34.SA": {
        "short_name": "DANAHER CORPDRN",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Washington"
    },
    "DHR": {
        "short_name": "Danaher Corporation",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Washington"
    },
    "DHR-PA": {
        "short_name": "Danaher Corporation 4.75% Manda",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Washington"
    },
    "DHR-PB": {
        "short_name": "Danaher Corporation 5.00% Manda",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Washington"
    },
    "DHR.MX": {
        "short_name": "DANAHER CORP",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Washington"
    },
    "DHRC.VI": {
        "short_name": "DANAHER CORP",
        "long_name": "Danaher Corporation",
        "summary": "Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Washington"
    },
    "DIA.MI": {
        "short_name": "DIASORIN",
        "long_name": "DiaSorin S.p.A.",
        "summary": "DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MIL",
        "market": "it_market",
        "country": "Italy",
        "city": "Saluggia"
    },
    "DIAS.VI": {
        "short_name": "DIASORIN SPA",
        "long_name": "DiaSorin S.p.A.",
        "summary": "DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Italy",
        "city": "Saluggia"
    },
    "DIGP": {
        "short_name": "DIGIPATH INC",
        "long_name": "DigiPath, Inc.",
        "summary": "DigiPath, Inc., together with its subsidiaries, provides cannabis and hemp lab testing services in the United States. The company offers cannabis lab testing services in Las Vegas to Nevada licensed medical marijuana enterprises. It also provides testing, cannabis education and training, and unbiased cannabis news coverage to the cannabis industry. The company operates as a testing laboratory facility for cannabis, cannabis infused products, hemp, and other botanical nutraceuticals to serve growers, dispensaries, caregivers, producers, patients, and end users of cannabis and botanical products. DigiPath, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Las Vegas"
    },
    "DMTK": {
        "short_name": "DermTech, Inc.",
        "long_name": "DermTech, Inc.",
        "summary": "DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "DRIO": {
        "short_name": "DarioHealth Corp.",
        "long_name": "DarioHealth Corp.",
        "summary": "DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "DSRLF": {
        "short_name": "DIASORIN SPA",
        "long_name": "DiaSorin S.p.A.",
        "summary": "DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Italy",
        "city": "Saluggia"
    },
    "DWV.F": {
        "short_name": "ANGLE PLC  LS-,10",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "DXCM": {
        "short_name": "DexCom, Inc.",
        "long_name": "DexCom, Inc.",
        "summary": "DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; a collaboration with Companion Medical, Inc.; and a development and commercialization agreement with Tandem Diabetes Care, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "DXCM.MX": {
        "short_name": "DEXCOM INC",
        "long_name": "DexCom, Inc.",
        "summary": "DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; a collaboration with Companion Medical, Inc.; and a development and commercialization agreement with Tandem Diabetes Care, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "San Diego"
    },
    "E08A.F": {
        "short_name": "EXAGEN INC.  DL-,001",
        "long_name": "Exagen Inc.",
        "summary": "Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Vista"
    },
    "ECX.DE": {
        "short_name": "EPIGENOMICS AG NA O.N.",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EDT.TO": {
        "short_name": "SPECTRAL MEDICAL INC",
        "long_name": "Spectral Medical Inc.",
        "summary": "Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy and continuous renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "EDTXF": {
        "short_name": "SPECTRAL MEDICAL INC",
        "long_name": "Spectral Medical Inc.",
        "summary": "Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy and continuous renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "EEP.MC": {
        "short_name": "EUROESPES, S.A.",
        "long_name": "Euroespes, S.A.",
        "summary": "Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as digital diagnosis, neuro-psychology, neuro-otolaryngology, neuro-ophthalmology, nursing, radioa diagnosis, and laboratory services. In addition, it offers pharmacogenetic cards; biotechnology; and a range of nutraceuticals. The company was founded in 1991 and is based in Corunna, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Corunna"
    },
    "EGQ.F": {
        "short_name": "BARD1 LIFE SCIENCES",
        "long_name": "BARD1 Life Sciences Limited",
        "summary": "BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "South Perth"
    },
    "EIY2.F": {
        "short_name": "RELAY MEDICAL",
        "long_name": "Relay Medical Corp.",
        "summary": "Relay Medical Corp. develops and sells products in the medical device, consumer health, and health IT industries. The company focuses on the development of novel technologies in the diagnostics and AI data science sectors. It provides HemoPalm, a handheld blood analyzer and single-use cartridge system for point-of-care blood gas and CO-oximetry testing; and Pharmatrac, an AI and data analytics driven personal medication management system for non-adherence to treatment. It also provides products and services related to the management of decentralized fleets of medical devices, and the data streams. The company was formerly known as ChroMedX Corp. and changed its name to Relay Medical Corp. in June 2018. Relay Medical Corp. is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "EKF.L": {
        "short_name": "EKF DIAGNOSTICS HOLDINGS PLC OR",
        "long_name": "EKF Diagnostics Holdings plc",
        "summary": "EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company offers Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; sTNFRr1, a predictive marker of end stage renal disease; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and RaPET Serology immunoassay kits, as well as reagents, calibrators, standards, and controls. Additionally, it provides contract manufacturing services, as well as services and distributes third party company's products. It sells its products directly to hospitals, laboratories, and government agencies, as well as through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "ENZ": {
        "short_name": "Enzo Biochem, Inc.",
        "long_name": "Enzo Biochem, Inc.",
        "summary": "Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing \u00c2\u0091STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "EPGND": {
        "short_name": "EPIGENOMICS AG",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EPGNF": {
        "short_name": "EPIGENOMICS AG",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EPGNY": {
        "short_name": "EPIGENOMICS AG",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EPLYF": {
        "short_name": "EPS HOLDINGS INC",
        "long_name": "EPS Holdings, Inc.",
        "summary": "EPS Holdings, Inc., through its subsidiaries, provides outsourced solutions to customers in the healthcare industry. It provides contract research organization (CRO) services and management of CRO segment activities; site management organization services; contract MR services, DI, and other call center services related BPO services, as well as medical device support services; contract sales solutions, including recruitment, training, and development of MRs (permanent, contract staffing, and temp to-perm), as well as medical communications programs and training; and promotion and BPO services for healthcare companies. The company also engages in clinical research related business; provision of IT services for pharmaceutical and medical settings; the import and export of products for non-clinical research, and provision of distribution services; research and development, manufacture, and sale of pharmaceuticals and medical devices; and provision of human studies (functionality and safety evaluations), basic research and animal studies, food composition analysis, research on functional substances, and other research and analysis services, as well as consulting in support of functional food development and other activities. In addition, it engages in trading, investment, and other businesses; shared services; rental and sale of advanced medical and other devices; and sale of clinical trial and other types of life and non-life insurance. The company serves pharmaceutical companies, medical device manufacturers, pharmaceutical development ventures, medical institutions, and universities and research institution in Japan and Asia. EPS Holdings, Inc. was founded in 1991 and is based in Tokyo, Japan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "ERFSF": {
        "short_name": "EUROFINS SCIENTIFIC SE",
        "long_name": "Eurofins Scientific SE",
        "summary": "Eurofins Scientific SE, through its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as for clinical diagnostic. It provides agro science, agro testing, biopharma, contract development and manufacturing organization, clinical diagnostics, consumer product testing, digital testing, electrical and electronics, environment testing, food and feed testing, forensic, genomic, industrial, materials and engineering, medical device, and REACH services. The company serves clients from a range of industries, including the pharmaceutical, food, environmental, and clinical diagnostics sectors. It operates approximately 800 laboratories in 50 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Luxembourg",
        "city": "Luxembourg City"
    },
    "EXAS": {
        "short_name": "Exact Sciences Corporation",
        "long_name": "Exact Sciences Corporation",
        "summary": "Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Madison"
    },
    "EXK.F": {
        "short_name": "EXACT SCIEN.  DL-,01",
        "long_name": "Exact Sciences Corporation",
        "summary": "Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Madison"
    },
    "EYWN.F": {
        "short_name": "BIOMERIEUX (P.S.)  O.N.",
        "long_name": "bioM\u00e9rieux S.A.",
        "summary": "bioM\u00c3\u00a9rieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D M\u00c3\u00a9rieux. bioM\u00c3\u00a9rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioM\u00c3\u00a9rieux S.A. is a subsidiary of Institut M\u00c3\u00a9rieux SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Marcy l'\u00c3\u0089toile"
    },
    "EZB.F": {
        "short_name": "ENZO BIOCHEM. INC. DL-,01",
        "long_name": "Enzo Biochem, Inc.",
        "summary": "Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing \u00c2\u0091STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "FLDM": {
        "short_name": "Fluidigm Corporation",
        "long_name": "Fluidigm Corporation",
        "summary": "Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "FLGT": {
        "short_name": "Fulgent Genetics, Inc.",
        "long_name": "Fulgent Genetics, Inc.",
        "summary": "Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home Covid-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Temple City"
    },
    "FLGT.MX": {
        "short_name": "FULGENT GENETICS INC",
        "long_name": "Fulgent Genetics, Inc.",
        "summary": "Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home Covid-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Temple City"
    },
    "GDR.L": {
        "short_name": "GENEDRIVE PLC ORD 1.5P",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "GENE": {
        "short_name": "Genetic Technologies Ltd",
        "long_name": "Genetic Technologies Limited",
        "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Australia",
        "city": "Fitzroy"
    },
    "GH": {
        "short_name": "Guardant Health, Inc.",
        "long_name": "Guardant Health, Inc.",
        "summary": "Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has a collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant; and has partnership with Vall d'Hebron Institute of Oncology to establish first guardant-based liquid biopsy testing service in Europe. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "GTG.AX": {
        "short_name": "GENE TECH FPO",
        "long_name": "Genetic Technologies Limited",
        "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Fitzroy"
    },
    "GTH": {
        "short_name": "Genetron Holdings Limited",
        "long_name": "Genetron Holdings Limited",
        "summary": "Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a partnership agreement with dMed Biopharmaceutical for new drug research and development in the field of oncology. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "city": "Beijing"
    },
    "GWHP": {
        "short_name": "GLOBAL WHOLEHEALTH PARTNERS COR",
        "long_name": "Global WholeHealth Partners Corporation",
        "summary": "Global WholeHealth Partners Corporation manufactures and markets various in vitro diagnostic test kits in the United States. It offers rapid diagnostic tests, such as the CoVid-19 test, whole blood Ebola test, whole blood Zika test, whole blood rapid TB test, and various other tests for over-the-counter or consumer-use, as well as point-of-care, which includes hospitals, physicians' offices, and medical clinics. The company was incorporated in 2013 and is based in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Clemente"
    },
    "HCLC": {
        "short_name": "HEALTH-CHEM CORP",
        "long_name": "Health-Chem Corporation",
        "summary": "Health-Chem Corporation, through its subsidiary, Transderm Laboratories Corporation, engages in the research, development, manufacture, and marketing of transdermal drug delivery systems in the United States. It offers transdermal nitroglycerin patches used for transdermal relief of the vascular and cardiovascular symptoms related to angina pectoris (chest pain). The company also conducts research and development activities for third parties on a contract basis. Health-Chem Corporation markets its products directly to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations, as well as indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management companies. The company was founded in 1970 and is based in Emigsville, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Emigsville"
    },
    "HSKA": {
        "short_name": "Heska Corporation",
        "long_name": "Heska Corporation",
        "summary": "Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud and HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Loveland"
    },
    "HSKN.F": {
        "short_name": "HESKA RESTR. NEW DL-,001",
        "long_name": "Heska Corporation",
        "summary": "Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud and HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Loveland"
    },
    "HTGM": {
        "short_name": "HTG Molecular Diagnostics, Inc.",
        "long_name": "HTG Molecular Diagnostics, Inc.",
        "summary": "HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Tucson"
    },
    "I1DX34.SA": {
        "short_name": "IDEXX LABORADRN",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Westbrook"
    },
    "I1QV34.SA": {
        "short_name": "IQVIA HOLDINDRN",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Durham"
    },
    "IBX.AX": {
        "short_name": "IMAGIONBIO FPO",
        "long_name": "Imagion Biosystems Limited",
        "summary": "Imagion Biosystems Limited provides medical imaging technologies to detect and eliminate cancer. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company engages in the research and development of its MagSense system to detect HER2 breast cancers. It uses MagSense technology that is based on superparamagnetic relaxometry for early cancer detection, cancer staging, and therapeutic monitoring. The company was founded in 1996 and is based in San Diego, California.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United States",
        "city": "San Diego"
    },
    "IBXXF": {
        "short_name": "IMAGION BIOSYSTEMS LIMITED",
        "long_name": "Imagion Biosystems Limited",
        "summary": "Imagion Biosystems Limited provides medical imaging technologies to detect and eliminate cancer. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company engages in the research and development of its MagSense system to detect HER2 breast cancers. It uses MagSense technology that is based on superparamagnetic relaxometry for early cancer detection, cancer staging, and therapeutic monitoring. The company was founded in 1996 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ICBU": {
        "short_name": "IMD COMPANIES INC",
        "long_name": "iMD Companies, Inc.",
        "summary": "iMD Companies, Inc. is a holding company which, through its subsidiaries, manufactures, markets, and distributes equipment for the hydroponics industry.  It also develops and manufactures environmental controllers. iMD Companies, Inc. is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Tampa"
    },
    "ICLR": {
        "short_name": "ICON plc",
        "long_name": "ICON Public Limited Company",
        "summary": "ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "IDHC.L": {
        "short_name": "INTEGRATED DIAGNOSTICS HOLDINGS",
        "long_name": "Integrated Diagnostics Holdings plc",
        "summary": "Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 1,400 diagnostic test services, including immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company provides its services primarily under the Al Borg, Al Borg Scan, Al Mokhtaba, and Wayak brands in Egypt; Biolab brand in Jordan; Ultralab and Al Mokhtabar Sudan brands in Sudan; and Echo-Lab in Nigeria. As of December 31, 2019, it operated a network of 452 labs. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "Jersey",
        "city": "Saint Helier"
    },
    "IDTA": {
        "short_name": "IDENTA CORP",
        "long_name": "IDenta Corp.",
        "summary": "IDenta Corp. manufactures and sells detection and forensic science equipment worldwide. The company offers drug, explosives, and bullet-hole testing kits; precursors of drugs test kits; and portable sniffers. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. IDenta Corp. is based in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "IDXG": {
        "short_name": "Interpace Biosciences, Inc.",
        "long_name": "Interpace Biosciences, Inc.",
        "summary": "Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Parsippany"
    },
    "IDXX": {
        "short_name": "IDEXX Laboratories, Inc.",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Westbrook"
    },
    "IDXX.VI": {
        "short_name": "IDEXX LABORATORIES INC",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Westbrook"
    },
    "IGPH.SW": {
        "short_name": "IGEA Pharma N",
        "long_name": "IGEA Pharma N.V.",
        "summary": "IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in in the United States. The company offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; and dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand. It also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. The company also engages in laboratory analysis. IGEA Pharma N.V. was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Netherlands",
        "city": "Hoofddorp"
    },
    "IHTI": {
        "short_name": "INTEGRATIVE HEALTH TECHNOLOGIES",
        "long_name": "Integrative Health Technologies, Inc.",
        "summary": "Integrative Health Technologies, Inc. provides fee-based clinical trials, research and development, and consulting and testing services to the healthcare and nutritional industries. The company maintains a database that contains more than 30,000 tests and dates back more than 20 years which tracks the footprints of diseases. It also operates mobile and stationary dual energy x-ray absorptiometry (DEXA) body composition scanning units for measuring total body and regional bone densities, and body fat and lean mass. In addition, the company provides blood chemistry testing report that provides 43 chemistries, including HDL, LDL, C-reactive protein, thyroid, electrolytes, red and white blood cell counts, and glucose, etc. Integrative Health Technologies, Inc. was founded in 1999 and is based in San Antonio, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Antonio"
    },
    "IJF.F": {
        "short_name": "ICON PLC  EO-,06",
        "long_name": "ICON Public Limited Company",
        "summary": "ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "ILMN": {
        "short_name": "Illumina, Inc.",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ILMN.MX": {
        "short_name": "ILLUMINA INC",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ILMN.VI": {
        "short_name": "ILLUMINA INC",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ILU.DE": {
        "short_name": "ILLUMINA INC.  DL-,01",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ILU.F": {
        "short_name": "ILLUMINA INC.  DL-,01",
        "long_name": "Illumina, Inc.",
        "summary": "Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "IMMNOV.ST": {
        "short_name": "Immunovia AB",
        "long_name": "Immunovia AB (publ)",
        "summary": "Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. The company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "IQV": {
        "short_name": "IQVIA Holdings, Inc.",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Durham"
    },
    "IQV.MX": {
        "short_name": "IQVIA HOLDINGS INC",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Durham"
    },
    "IQVH.VI": {
        "short_name": "IQVIA HOLDINGS INC",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Durham"
    },
    "IV8.F": {
        "short_name": "INVITAE CORP.  DL-,0001",
        "long_name": "Invitae Corporation",
        "summary": "Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy; and a project with Bristol Myers Squibb, Janssen Research & Development, LLC, Novartis, and Genentech to develop a panel for molecular residual disease detection in patients with acute myeloid leukemia to support clinical trial testing across various drug development programs. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "IVRO": {
        "short_name": "INVITRO INTERNATIONAL",
        "long_name": "InVitro International",
        "summary": "InVitro International develops test kits for non-animal testing in the United States and internationally. Its products include Irritection Assay System, an invitro test, which could be used to detect, rank, and predict the ocular and/or dermal irritation potential of cosmetics, consumer products, pharmaceuticals, and chemical raw materials; and Corrositex, an invitro test that determines chemical corrosivity. The company also provides customized technology services for Irritection Assay System installation and testing process, as well as independent testing laboratory services for irritancy and corrosivity testing requirements. Its products are principally used by the manufacturers of surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other chemical raw materials. The company was founded in 1985 and is headquartered in Placentia, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Placentia"
    },
    "IWKS": {
        "short_name": "AFP IMAGING CORP",
        "long_name": "ImageWorks Corporation",
        "summary": "ImageWorks Corporation provides imaging solutions to the dental health professionals. It offers panoramic and 3D imaging products, intraoral X-rays, and digital sensors, as well as dental imaging software. The company was formerly known as AFP Imaging Corporation and changed its name to ImageWorks Corporation in June 2010. Imageworks Corporation was founded in 1978 and is based in Elmsford, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Elmsford"
    },
    "IX1.F": {
        "short_name": "IDEXX LABS INC.  DL-,10",
        "long_name": "IDEXX Laboratories, Inc.",
        "summary": "IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Westbrook"
    },
    "IZO.CN": {
        "short_name": "IzotropicCorp",
        "long_name": "Izotropic Corporation",
        "summary": "Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3D breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Surrey"
    },
    "IZOZF": {
        "short_name": "IZOTROPIC CORPORATION",
        "long_name": "Izotropic Corporation",
        "summary": "Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3D breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Surrey"
    },
    "JUMP.V": {
        "short_name": "LEVELJUMP HEALTHCARE CORP",
        "long_name": "Leveljump Healthcare Corp.",
        "summary": "Leveljump Healthcare Corp. operates as a medical diagnostic imaging company. It offers teleradiology services to its client hospitals and imaging centers. The company is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "LALPATHLAB.NS": {
        "short_name": "DR LAL PATHLABS LT",
        "long_name": "Dr. Lal PathLabs Limited",
        "summary": "Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company offers pathology and radiology testing; lab staff training; technical; and lab management services. As of March 31, 2020, the company had 216 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 3,095 patient service centers and 6,995 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Gurugram"
    },
    "LBIRD.PA": {
        "short_name": "LUMIBIRD",
        "long_name": "Lumibird SA",
        "summary": "Lumibird SA designs, manufactures, and markets various lasers for the scientific, industrial, and medical markets in France, Europe, the United States, and Asia. It operates in two divisions, Laser and Medical. The Laser division offers products based on fiber laser, solid-state laser, and laser diode technologies for use in industrial, defense, scientific, and medical applications. Its products primarily include solid-state lasers and pulsed laser diodes, fiber lasers and amplifiers, and laser-based electro-optical systems. The Medical division provides diagnostic and treatment equipment for ophthalmology based on lasers and ultrasonic sensors, such as lasers and echographs. The company was founded in 1970 and is based in Lannion, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lannion"
    },
    "LH": {
        "short_name": "Laboratory Corporation of Ameri",
        "long_name": "Laboratory Corporation of America Holdings",
        "summary": "Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular and infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other procedures. In addition, it provides a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, QIAGEN N.V, Ciox Health, Circuit Clinical, and Riverside Medical Group. The company was founded in 1971 and is headquartered in Burlington, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Burlington"
    },
    "LNTH": {
        "short_name": "Lantheus Holdings, Inc.",
        "long_name": "Lantheus Holdings, Inc.",
        "summary": "Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201 for use in MPI studies to detect cardiovascular disease; Gallium Ga 67 to detect various infections and cancerous tumors; and Quadramet, a therapeutic product. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment of neuroendocrine tumors. It serves radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic collaborations with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting R&D on PD-L1 immuno-oncology treatments; Insightec Ltd. for the treatment of glioblastoma and neurodegenerative conditions; and POINT Biopharma, Inc. to treat metastatic castration resistant prostate cancer. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "North Billerica"
    },
    "LONN.SW": {
        "short_name": "LONZA N",
        "long_name": "Lonza Group Ltd",
        "summary": "Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment operates microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273; and an agreement with Capricor Therapeutics, Inc. for the development of CAP-1002, a clinical asset for the treatment of Duchenne Muscular Dystrophy and complications arising from COVID-19. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "LZAGF": {
        "short_name": "LONZA GROUP AG",
        "long_name": "Lonza Group Ltd",
        "summary": "Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment operates microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273; and an agreement with Capricor Therapeutics, Inc. for the development of CAP-1002, a clinical asset for the treatment of Duchenne Muscular Dystrophy and complications arising from COVID-19. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "LZAGY": {
        "short_name": "LONZA GROUP AG",
        "long_name": "Lonza Group Ltd",
        "summary": "Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment operates microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273; and an agreement with Capricor Therapeutics, Inc. for the development of CAP-1002, a clinical asset for the treatment of Duchenne Muscular Dystrophy and complications arising from COVID-19. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "M1TD34.SA": {
        "short_name": "METTLER-TOLEDRN",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a PC-based laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. The company markets its products through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Columbus"
    },
    "MBI-H.V": {
        "short_name": "MED BIOGENE INC",
        "long_name": "Med BioGene Inc.",
        "summary": "Med BioGene Inc. does not have significant operations. Previously, the company was engaged in the life science business with a focus on the development and commercialization of genomic-based clinical tests for cancer. The company focuses on the commercialization of technologies in various industrial sectors. Med BioGene Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "MDXH.BR": {
        "short_name": "MDXHEALTH",
        "long_name": "MDxHealth SA",
        "summary": "MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Belgium, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Herstal"
    },
    "MEDD": {
        "short_name": "MEDICAL IMAGING CORP",
        "long_name": "Medical Imaging Corp.",
        "summary": "Medical Imaging Corp., through its subsidiaries, provides medical diagnostic imaging services for patients, hospitals and clinics, workers' compensation boards, and insurance companies in North America. It provides remote reading and reporting of medical diagnostic imaging scans. The company also provides magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, nuclear medicine, digital mammography, X-ray, and bone mineral densitometry modalities. As of December 31, 2017, it operated an independent diagnostic imaging facility in Pottsville, Pennsylvania; and three diagnostic centers in Florida. The company was formerly known as Diagnostic Imaging International Corp. and changed its name to Medical Imaging Corp. in July 2014. Medical Imaging Corp. was incorporated in 2000 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Las Vegas"
    },
    "MEDP": {
        "short_name": "Medpace Holdings, Inc.",
        "long_name": "Medpace Holdings, Inc.",
        "summary": "Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cincinnati"
    },
    "MEDP.MX": {
        "short_name": "MEDPACE HOLDINGS INC",
        "long_name": "Medpace Holdings, Inc.",
        "summary": "Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Cincinnati"
    },
    "MIS.F": {
        "short_name": "MONASH IVF GROUP LTD",
        "long_name": "Monash IVF Group Limited",
        "summary": "Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnosis and treatment of infertility, fertility research and treatment services, tertiary level prenatal diagnostic services, low intervention IVF services, and diagnostic ultrasound services. Monash IVF Group Limited was incorporated in 2014 and is based in Richmond, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Richmond"
    },
    "MLAHC.PA": {
        "short_name": "HEALTH",
        "long_name": "@Health SA",
        "summary": "@Health SA, an e-cardiology company, develops medical devices worldwide. It offers CardioNexion, a medical device for the ultra-early detection and analysis of all cardiovascular pathologies. The company is based in Aix-en-Provence, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Aix-en-Provence"
    },
    "MOTS": {
        "short_name": "Motus GI Holdings, Inc.",
        "long_name": "Motus GI Holdings, Inc.",
        "summary": "Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company is based in Fort Lauderdale, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Fort Lauderdale"
    },
    "MRPS": {
        "short_name": "MICROPHONICS INC",
        "long_name": "Microphonics, Inc.",
        "summary": "Microphonics Inc. develops, manufactures, and markets ultrasound diagnostic and detection equipments and speech recognition systems for industrial, manufacturing, governmental, agricultural, automotive, professional racing, and medical markets. The company deploys its ultrasound and electronic technology for acoustical ultrasound of mechanical diagnostic evaluations. Microphonics Inc. is based in Nashville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Nashville"
    },
    "MTD": {
        "short_name": "Mettler-Toledo International, I",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a PC-based laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. The company markets its products through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Columbus"
    },
    "MTD.MX": {
        "short_name": "METTLER-TOLEDO INTERNATIONAL IN",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a PC-based laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. The company markets its products through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Columbus"
    },
    "MTO.DE": {
        "short_name": "METTLER-TOLEDO INTL",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a PC-based laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. The company markets its products through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Columbus"
    },
    "MTO.F": {
        "short_name": "METTLER-TOLEDO INTL",
        "long_name": "Mettler-Toledo International Inc.",
        "summary": "Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a PC-based laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. The company markets its products through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Columbus"
    },
    "MVF.AX": {
        "short_name": "MONASH IVF FPO",
        "long_name": "Monash IVF Group Limited",
        "summary": "Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnosis and treatment of infertility, fertility research and treatment services, tertiary level prenatal diagnostic services, low intervention IVF services, and diagnostic ultrasound services. Monash IVF Group Limited was incorporated in 2014 and is based in Richmond, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Richmond"
    },
    "MXCL.L": {
        "short_name": "MAXCYTE INC COM STK USD0.01 (DI",
        "long_name": "MaxCyte, Inc.",
        "summary": "MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "MXCT.L": {
        "short_name": "MAXCYTE INC COM STK USD0.01 (DI",
        "long_name": "MaxCyte, Inc.",
        "summary": "MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "MXDHF": {
        "short_name": "MDXHEALTH",
        "long_name": "MDxHealth SA",
        "summary": "MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Belgium, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Belgium",
        "city": "Herstal"
    },
    "MYD.DE": {
        "short_name": "MYRIAD GENETICS  DL-,01",
        "long_name": "Myriad Genetics, Inc.",
        "summary": "Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "MYD.F": {
        "short_name": "MYRIAD GENETICS  DL-,01",
        "long_name": "Myriad Genetics, Inc.",
        "summary": "Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "MYE0.F": {
        "short_name": "MAXCYTE INC  DL-,01",
        "long_name": "MaxCyte, Inc.",
        "summary": "MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "MYGN": {
        "short_name": "Myriad Genetics, Inc.",
        "long_name": "Myriad Genetics, Inc.",
        "summary": "Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "NCYT.L": {
        "short_name": "NOVACYT S.A. EUR1/15TH (CDI)",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "NDRA": {
        "short_name": "ENDRA Life Sciences Inc.",
        "long_name": "ENDRA Life Sciences Inc.",
        "summary": "ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Ann Arbor"
    },
    "NEO": {
        "short_name": "NeoGenomics, Inc.",
        "long_name": "NeoGenomics, Inc.",
        "summary": "NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Fort Myers"
    },
    "NEO.MX": {
        "short_name": "NEOGENOMICS INC",
        "long_name": "NeoGenomics, Inc.",
        "summary": "NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Fort Myers"
    },
    "NEOG": {
        "short_name": "Neogen Corporation",
        "long_name": "Neogen Corporation",
        "summary": "Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lansing"
    },
    "NG2.F": {
        "short_name": "NEOGEN CORP.  DL-,16",
        "long_name": "Neogen Corporation",
        "summary": "Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lansing"
    },
    "NG9.F": {
        "short_name": "NEOGENOMICSINC.  DL-,001",
        "long_name": "NeoGenomics, Inc.",
        "summary": "NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Fort Myers"
    },
    "NLAB": {
        "short_name": "NUONCOLOGY LABORATORIES INC",
        "long_name": "NuOncology Labs, Inc.",
        "summary": "NuOncology Labs, Inc. engages in the research, development, testing, and licensing of cancer treatments, and medical and agricultural compounds; and the delivery of predictive chemosensitivity tests, as of December 31, 1998. It served surgeons, oncologists, pathologists, hospitals, health maintenance organizations, community health centers, and third party insurance companies in the United States. The company is based in Virginia Beach, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Virginia Beach"
    },
    "NN6.DE": {
        "short_name": "NANOREPRO AG",
        "long_name": "NanoRepro AG",
        "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Marburg"
    },
    "NN6.F": {
        "short_name": "NANOREPRO AG",
        "long_name": "NanoRepro AG",
        "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Marburg"
    },
    "NRC": {
        "short_name": "National Research Corporation",
        "long_name": "National Research Corporation",
        "summary": "National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions; and health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lincoln"
    },
    "NRC.F": {
        "short_name": "NEURONETICS INC.  DL-,01",
        "long_name": "Neuronetics, Inc.",
        "summary": "Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Malvern"
    },
    "NSTM": {
        "short_name": "NOVELSTEM INTERNATIONAL CORP",
        "long_name": "NovelStem International Corp.",
        "summary": "NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients' resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. It has a collaboration agreement with NewStem Ltd. for stem-cell technology platform in cancer immunotherapy and COVID-19 resistance. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from advertising services to stem cell-based diagnostics for cancer chemotherapies. The company was founded in 1993 and is headquartered in Boca Raton, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Boca Raton"
    },
    "NTRA": {
        "short_name": "Natera, Inc.",
        "long_name": "Natera, Inc.",
        "summary": "Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Carlos"
    },
    "NVTA": {
        "short_name": "Invitae Corporation",
        "long_name": "Invitae Corporation",
        "summary": "Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy; and a project with Bristol Myers Squibb, Janssen Research & Development, LLC, Novartis, and Genentech to develop a panel for molecular residual disease detection in patients with acute myeloid leukemia to support clinical trial testing across various drug development programs. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "NVTA.MX": {
        "short_name": "INVITAE CORP",
        "long_name": "Invitae Corporation",
        "summary": "Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy; and a project with Bristol Myers Squibb, Janssen Research & Development, LLC, Novartis, and Genentech to develop a panel for molecular residual disease detection in patients with acute myeloid leukemia to support clinical trial testing across various drug development programs. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "NVYTF": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "NYZ.F": {
        "short_name": "NOVACYT  EO-,0667",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "O6C.F": {
        "short_name": "MDXHEALTH S.A.",
        "long_name": "MDxHealth SA",
        "summary": "MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Belgium, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Herstal"
    },
    "ONVO": {
        "short_name": "Organovo Holdings, Inc.",
        "long_name": "Organovo Holdings, Inc.",
        "summary": "Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Solana Beach"
    },
    "OPGN": {
        "short_name": "OpGen, Inc.",
        "long_name": "OpGen, Inc.",
        "summary": "OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "OPGX": {
        "short_name": "OPTIGENEX INC",
        "long_name": "Optigenex Inc.",
        "summary": "Optigenex Inc. engages in the manufacture and sale of healthy age management and beauty care products. The company offers AC-11, a powdered and bioactive rainforest plant extract that helps the body to repair sun and environmental stress-related damage to DNA, and slow down the process of skin aging. It serves manufacturers, distributors, and retailers worldwide in the dietary supplement, as well as anti-aging topical skin care, cosmetic, and cosmeceutical market categories. The company is based in Melissa, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Melissa"
    },
    "OPK": {
        "short_name": "Opko Health, Inc.",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Miami"
    },
    "OPK.MX": {
        "short_name": "OPKO HEALTH INC",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Miami"
    },
    "OPK.TA": {
        "short_name": "OPKO HEALTH INC",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TLV",
        "market": "il_market",
        "country": "United States",
        "city": "Miami"
    },
    "OXFD": {
        "short_name": "Oxford Immunotec Global PLC",
        "long_name": "Oxford Immunotec Global PLC",
        "summary": "Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Abingdon"
    },
    "P8A.SI": {
        "short_name": "Cordlife",
        "long_name": "Cordlife Group Limited",
        "summary": "Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, Macau, India, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines, Bangladesh, and internationally. It operates through two segments, Banking and Diagnostics. The company provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening, and family genetic screening services. It also offers management, marketing, and property investment services. The company was formerly known as Cordlife Pte Ltd and changed its name to Cordlife Group Limited in 2011. Cordlife Group Limited was founded in 2001 and is headquartered in Singapore.",
        "currency": "SGD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SES",
        "market": "sg_market",
        "country": "Singapore",
        "city": "Singapore"
    },
    "PACB": {
        "short_name": "Pacific Biosciences of Californ",
        "long_name": "Pacific Biosciences of California, Inc.",
        "summary": "Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. has collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "PANG.MC": {
        "short_name": "PANGAEA ONCOLOGY S.A.",
        "long_name": "Pangaea Oncology, S.A.",
        "summary": "Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide. It offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, Western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. The company also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2007 and is based in Barcelona, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Barcelona"
    },
    "PARD3.SA": {
        "short_name": "IHPARDINI   ON      NM",
        "long_name": "Instituto Hermes Pardini S.A.",
        "summary": "Instituto Hermes Pardini S.A., together with its subsidiaries, provides medical, dental, laboratory research, clinical analysis, and supplementary diagnostic and therapeutic services in Brazil. It offers clinical analysis tests, diagnostic imaging, vaccines, check-ups, and other diagnostic services through 124 centers in the states of Minas Gerais, Goi\u00c3\u00a1s, S\u00c3\u00a3o Paulo, and Rio de Janeiro. The company also provides lab-to-lab services, such as specialized tests for other laboratories, as well as consulting, training, and support services for its customers. It operates primarily through eight brands, including Hermes Pardini, Progen\u00c3\u00a9tica, Diagn\u00c3\u00b3stika, Biocod, DLE, Labfar, Toxicologia Pardini, and Solu\u00c3\u00a7\u00c3\u00a3o. The company serves hospitals, clinics, laboratories, and other companies in the health care sector. Instituto Hermes Pardini S.A. was founded in 1959 and is headquartered in Belo Horizonte, Brazil.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "Brazil",
        "city": "Belo Horizonte"
    },
    "PCHM": {
        "short_name": "PHARMCHEM INC",
        "long_name": "PharmChem, Inc.",
        "summary": "PharmChem, Inc. provides PharmChek Sweat Patch that is used to detect drugs of abuse. Its PharmChek Sweat Patch uses sweat as the source and offers alternative to urine testing for cocaine, opiates, amphetamines, PCP, and marijuana. The company is based in Fort Worth, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Fort Worth"
    },
    "PHG": {
        "short_name": "Koninklijke Philips N.V. NY Reg",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIA.AS": {
        "short_name": "PHILIPS KON",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIA.F": {
        "short_name": "KONINKL. PHILIPS ADR -,20",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIA.MI": {
        "short_name": "PHILIPS",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MIL",
        "market": "it_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PHIA.VI": {
        "short_name": "PHILIPS NV",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "PKI": {
        "short_name": "PerkinElmer, Inc.",
        "long_name": "PerkinElmer, Inc.",
        "summary": "PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "PKN.F": {
        "short_name": "PERKINELMER INC.  DL 1",
        "long_name": "PerkinElmer, Inc.",
        "summary": "PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Waltham"
    },
    "PMD": {
        "short_name": "Psychemedics Corporation",
        "long_name": "Psychemedics Corporation",
        "summary": "Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Acton"
    },
    "PMSNF": {
        "short_name": "PROTEOME SCIENCES",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro, and manufacture small, protein-reactive chemical reagents; and Elayta, a small molecule inhibitor of beta-amyloid interaction with synaptic receptors that modifies downstream signaling and provides neuroprotective effects. It offers SysQuant and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor; TMT Calibrator ?combines protein and fluid proteomics to identify tissue proteins with evidenced availability for peripheral detection; PD biomarker discovery; and TMT SRM and Immuno Assay for CDx biomarker validation. The company primarily serves pharmaceutical and biotechnology companies, including academic research. Proteome Sciences plc was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "PQIA.F": {
        "short_name": "RADNET INC.  DL-,01",
        "long_name": "RadNet, Inc.",
        "summary": "RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of hospitals and hospital-based radiology groups. As of December 31, 2019, it operated 335 centers in California, Delaware, Florida, Maryland, New Jersey, and New York. RadNet, Inc. has a collaboration with Hologic, Inc. to advance the use of artificial intelligence in breast health. The company was founded in 1985 and is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "PRAH": {
        "short_name": "PRA Health Sciences, Inc.",
        "long_name": "PRA Health Sciences, Inc.",
        "summary": "PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Raleigh"
    },
    "PRDA.JK": {
        "short_name": "Prodia Widyahusada Tbk.",
        "long_name": "PT Prodia Widyahusada Tbk",
        "summary": "PT Prodia Widyahusada Tbk provides private clinical laboratory services. The company offers laboratory and panel test services; and other diagnostics support services. It operates through a network of 151 branches and outlets in Indonesia. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Prodia Widyahusada Tbk is a subsidiary of PT Prodia Utama.",
        "currency": "IDR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "JKT",
        "market": "id_market",
        "country": "Indonesia",
        "city": "Jakarta Pusat"
    },
    "PROGEN.ST": {
        "short_name": "Prostatype Genomics AB",
        "long_name": "Prostatype Genomics AB (publ)",
        "summary": "Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype, a gene test for prostate cancer patients. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "PRPO": {
        "short_name": "Precipio, Inc.",
        "long_name": "Precipio, Inc.",
        "summary": "Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; and HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test. It serves oncologists, hospitals, reference laboratories, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine and Harvard's Dana-Farber Cancer Institute. The company is based in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New Haven"
    },
    "PSNL": {
        "short_name": "Personalis, Inc.",
        "long_name": "Personalis, Inc.",
        "summary": "Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "PVSP": {
        "short_name": "PERVASIP CORPORATION",
        "long_name": "Pervasip Corporation",
        "summary": "Pervasip Corporation focuses on developing cloud-based applications to monitor and control greenhouse facilities. It intends to develop and deliver products and technologies to agricultural markets; develop scientific methods for the analysis of cannabinoids in flowers, concentrates, and edibles; and assist medical marijuana specialty production facilities to regulate, calculate proper dosage, and understand the importance of consistency in product. The company was formerly known as eLEC Communications Corp. and changed its name to Pervasip Corp. in December 2007. Pervasip Corp. was founded in 1964 and is based in White Plains, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "White Plains"
    },
    "QDEL": {
        "short_name": "Quidel Corporation",
        "long_name": "Quidel Corporation",
        "summary": "Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "QGEN": {
        "short_name": "Qiagen N.V.",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QGEN.VI": {
        "short_name": "QIAGEN NV",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QIA.DE": {
        "short_name": "QIAGEN NV  EO -,01",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QIA.F": {
        "short_name": "QIAGEN NV  EO -,01",
        "long_name": "QIAGEN N.V.",
        "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Venlo"
    },
    "QL1.F": {
        "short_name": "QUIDEL CORP.  DL-,001",
        "long_name": "Quidel Corporation",
        "summary": "Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "QTNT": {
        "short_name": "Quotient Limited",
        "long_name": "Quotient Limited",
        "summary": "Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Eysins"
    },
    "QTS.DE": {
        "short_name": "IQVIA HLDGS  DL-,01",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Durham"
    },
    "QTS.F": {
        "short_name": "IQVIA HLDGS  DL-,01",
        "long_name": "IQVIA Holdings Inc.",
        "summary": "IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Durham"
    },
    "RDNT": {
        "short_name": "RadNet, Inc.",
        "long_name": "RadNet, Inc.",
        "summary": "RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of hospitals and hospital-based radiology groups. As of December 31, 2019, it operated 335 centers in California, Delaware, Florida, Maryland, New Jersey, and New York. RadNet, Inc. has a collaboration with Hologic, Inc. to advance the use of artificial intelligence in breast health. The company was founded in 1985 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "RELA.CN": {
        "short_name": "RelayMedCorp",
        "long_name": "Relay Medical Corp.",
        "summary": "Relay Medical Corp. develops and sells products in the medical device, consumer health, and health IT industries. The company focuses on the development of novel technologies in the diagnostics and AI data science sectors. It provides HemoPalm, a handheld blood analyzer and single-use cartridge system for point-of-care blood gas and CO-oximetry testing; and Pharmatrac, an AI and data analytics driven personal medication management system for non-adherence to treatment. It also provides products and services related to the management of decentralized fleets of medical devices, and the data streams. The company was formerly known as ChroMedX Corp. and changed its name to Relay Medical Corp. in June 2018. Relay Medical Corp. is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "RENX.L": {
        "short_name": "RENALYTIX AI PLC ORD 0.25P",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RGDXQ": {
        "short_name": "RESPONSE GENETICS INC",
        "long_name": "Response Genetics, Inc",
        "summary": "Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "RHY.AX": {
        "short_name": "RHYTHM BIO FPO",
        "long_name": "Rhythm Biosciences Limited",
        "summary": "Rhythm Biosciences Limited engages in developing and commercializing medical diagnostics technology in Australia and internationally. It is developing ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Parkville"
    },
    "RNLX": {
        "short_name": "Renalytix AI plc",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RNVA": {
        "short_name": "Rennova Health, Inc.",
        "long_name": "Rennova Health, Inc.",
        "summary": "Rennova Health, Inc., together with its subsidiaries, engages in the hospital operations in the United States. It operates in two segments, Hospital Operations and Clinical Laboratory Services. The company provides a suite of healthcare related products and services for healthcare providers, patients, and individuals. It also offers diagnostic imaging, radiology, surgery, nuclear medicine, wound care and hyperbaric medicine, intensive care, emergency care, and physical therapy services; and X-ray, mammography, bone densitometry, computed tomography, ultrasound, physical therapy, and laboratory services. In addition, the company provides blood and urine, toxicology, clinical pharmacogenetics, and esoteric testing services. Further, it invests in and develops a suite of software products to its diagnostics business. Additionally, the company owns three hospitals, a physician's office in Tennessee, and a rural clinic in Kentucky. Rennova Health, Inc. was founded in 2005 and is based in West Palm Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "West Palm Beach"
    },
    "ROSGQ": {
        "short_name": "ROSETTA GENOMICS LTD",
        "long_name": "Rosetta Genomics Ltd.",
        "summary": "Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "RTNXF": {
        "short_name": "RENALYTIX AI PLC",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RYLPF": {
        "short_name": "KONINKLIJKE PHILIPS NV",
        "long_name": "Koninklijke Philips N.V.",
        "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "RYMDF": {
        "short_name": "RELAY MEDICAL CORP",
        "long_name": "Relay Medical Corp.",
        "summary": "Relay Medical Corp. develops and sells products in the medical device, consumer health, and health IT industries. The company focuses on the development of novel technologies in the diagnostics and AI data science sectors. It provides HemoPalm, a handheld blood analyzer and single-use cartridge system for point-of-care blood gas and CO-oximetry testing; and Pharmatrac, an AI and data analytics driven personal medication management system for non-adherence to treatment. It also provides products and services related to the management of decentralized fleets of medical devices, and the data streams. The company was formerly known as ChroMedX Corp. and changed its name to Relay Medical Corp. in June 2018. Relay Medical Corp. is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SENS": {
        "short_name": "Senseonics Holdings, Inc.",
        "long_name": "Senseonics Holdings, Inc.",
        "summary": "Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes for a period of up to 90 and 180 days. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Germantown"
    },
    "SENZA.ST": {
        "short_name": "SenzaGen AB",
        "long_name": "SenzaGen AB",
        "summary": "SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally. It offers GARDskin for predicting the ability of chemicals to induce sensitization; GARDpotency, an animal free test to subcategorize sensitizers according to CLP/GHS classifications by monitoring the expression of 50 complementary genomic biomarkers; and GARDair, an in vitro assay for the prediction of chemical respiratory sensitizers. The company also provides GARDskin medical devices. It offers services through distributors, laboratories, and licensed contract research organizations. SenzaGen AB has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was founded in 2010 and is headquartered in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "SH5.MU": {
        "short_name": "SOTERA HEALTH COMPANY",
        "long_name": "Sotera Health Company",
        "summary": "Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the United States and internationally. Its sterilization services include gamma and electron beam irradiation, and EO processing; and lab services comprise analytical chemistry, medical device, and pharmaceutical lab testing, as well as microbiology testing. The company also provides Co-60 and gamma irradiators, which are principal components to the gamma sterilization process. Its microbiology testing services help customers to identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained; and advisory services help customers in navigating the regulatory requirements applicable throughout the product lifecycle. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is based in Broadview Heights, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "Broadview Heights"
    },
    "SHC": {
        "short_name": "Sotera Health Company",
        "long_name": "Sotera Health Company",
        "summary": "Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the United States and internationally. Its sterilization services include gamma and electron beam irradiation, and EO processing; and lab services comprise analytical chemistry, medical device, and pharmaceutical lab testing, as well as microbiology testing. The company also provides Co-60 and gamma irradiators, which are principal components to the gamma sterilization process. Its microbiology testing services help customers to identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained; and advisory services help customers in navigating the regulatory requirements applicable throughout the product lifecycle. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is based in Broadview Heights, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Broadview Heights"
    },
    "SHL.DE": {
        "short_name": "SIEMENS HEALTH.AG NA O.N.",
        "long_name": "Siemens Healthineers AG",
        "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Erlangen"
    },
    "SLNO": {
        "short_name": "Soleno Therapeutics, Inc.",
        "long_name": "Soleno Therapeutics, Inc.",
        "summary": "Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "SMMNY": {
        "short_name": "SIEMENS HEALTHINEERS AG",
        "long_name": "Siemens Healthineers AG",
        "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Erlangen"
    },
    "SQD.V": {
        "short_name": "SQI DIAGNOSTICS INC.",
        "long_name": "SQI Diagnostics Inc.",
        "summary": "SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for multiplexing diagnostics in Canada. It offers a range of multiplexed products and services, including detecting and quantifying proteins, antibodies, and DNA. The company provides sqidworks, a workhorse system that enables to load plates and get report; sqidlite, a benchtop system, which allows processing one plate per run; and sqid-X that accesses various multiplexing power of Ig_plex technology with its semi-automated system. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. The company serves pharmaceutical and biotechnology drug development, human diagnostic testing, and animal health diagnostic testing markets. SQI Diagnostics Inc. was founded in 1999 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SQIDF": {
        "short_name": "SQI DIAGNOSTICS INC",
        "long_name": "SQI Diagnostics Inc.",
        "summary": "SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for multiplexing diagnostics in Canada. It offers a range of multiplexed products and services, including detecting and quantifying proteins, antibodies, and DNA. The company provides sqidworks, a workhorse system that enables to load plates and get report; sqidlite, a benchtop system, which allows processing one plate per run; and sqid-X that accesses various multiplexing power of Ig_plex technology with its semi-automated system. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. The company serves pharmaceutical and biotechnology drug development, human diagnostic testing, and animal health diagnostic testing markets. SQI Diagnostics Inc. was founded in 1999 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SSMXF": {
        "short_name": "SYSMEX CORP",
        "long_name": "Sysmex Corporation",
        "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Japan",
        "city": "Kobe"
    },
    "SSMXY": {
        "short_name": "SYSMEX CORP",
        "long_name": "Sysmex Corporation",
        "summary": "Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Japan",
        "city": "Kobe"
    },
    "STIM": {
        "short_name": "Neuronetics, Inc.",
        "long_name": "Neuronetics, Inc.",
        "summary": "Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Malvern"
    },
    "SYNH": {
        "short_name": "Syneos Health, Inc.",
        "long_name": "Syneos Health, Inc.",
        "summary": "Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications solutions, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic agreement with Daiichi Sankyo, Inc. for the development of Daiichi Sankyo'S Adc oncology pipeline; and a partnership with VBI Vaccines Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "SZGEF": {
        "short_name": "SENZAGEN AB",
        "long_name": "SenzaGen AB",
        "summary": "SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally. It offers GARDskin for predicting the ability of chemicals to induce sensitization; GARDpotency, an animal free test to subcategorize sensitizers according to CLP/GHS classifications by monitoring the expression of 50 complementary genomic biomarkers; and GARDair, an in vitro assay for the prediction of chemical respiratory sensitizers. The company also provides GARDskin medical devices. It offers services through distributors, laboratories, and licensed contract research organizations. SenzaGen AB has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was founded in 2010 and is headquartered in Lund, Sweden.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "SZLS.TO": {
        "short_name": "STAGEZERO LIFE SCIENCES LTD",
        "long_name": "StageZero Life Sciences Ltd.",
        "summary": "StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Richmond Hill"
    },
    "TDLAF": {
        "short_name": "TBG DIAGNOSTICS LTD",
        "long_name": "TBG Diagnostics Limited",
        "summary": "TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Greenslopes"
    },
    "TDSGF": {
        "short_name": "TELO GENOMICS CORP",
        "long_name": "Telo Genomics Corp.",
        "summary": "Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "TELO.V": {
        "short_name": "TELO GENOMICS CORP",
        "long_name": "Telo Genomics Corp.",
        "summary": "Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "TGKQ.F": {
        "short_name": "PRECIPIO INC.  DL-,01",
        "long_name": "Precipio, Inc.",
        "summary": "Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; and HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test. It serves oncologists, hospitals, reference laboratories, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine and Harvard's Dana-Farber Cancer Institute. The company is based in New Haven, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New Haven"
    },
    "THYROCARE.NS": {
        "short_name": "THYROCARE TECHNOL",
        "long_name": "Thyrocare Technologies Limited",
        "summary": "Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. The company operates through Diagnostic Testing Services, Imaging Services, and Others segments. It conducts medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases. Its profiles of tests include 54 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company sells glucometer and glucostrips under the brand name Sugarscan; and radio-pharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Navi Mumbai"
    },
    "TMO": {
        "short_name": "Thermo Fisher Scientific Inc",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems and antibody tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; cancer diagnosis and medical research products; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, and ultralow-temperature freezers and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics and chemicals; and pharma services. It has collaboration with WuXi Diagnostics and Mayo Clinic to develop antibodies tests; a strategic collaboration with Schr\u00c3\u00b6dinger, Inc.; an agreement with Daiichi Sankyo; collaboration with Northeastern University; and partnership with Boys & Girls Clubs of America. The company was incorporated in 1956 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "TMO.MX": {
        "short_name": "THERMO FISHER SCIENTIFIC INC",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems and antibody tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; cancer diagnosis and medical research products; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, and ultralow-temperature freezers and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics and chemicals; and pharma services. It has collaboration with WuXi Diagnostics and Mayo Clinic to develop antibodies tests; a strategic collaboration with Schr\u00c3\u00b6dinger, Inc.; an agreement with Daiichi Sankyo; collaboration with Northeastern University; and partnership with Boys & Girls Clubs of America. The company was incorporated in 1956 and is headquartered in Waltham, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Waltham"
    },
    "TMOF.VI": {
        "short_name": "THERMO FISHER SCIENTIFIC INC",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems and antibody tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; cancer diagnosis and medical research products; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, and ultralow-temperature freezers and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics and chemicals; and pharma services. It has collaboration with WuXi Diagnostics and Mayo Clinic to develop antibodies tests; a strategic collaboration with Schr\u00c3\u00b6dinger, Inc.; an agreement with Daiichi Sankyo; collaboration with Northeastern University; and partnership with Boys & Girls Clubs of America. The company was incorporated in 1956 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Waltham"
    },
    "TMOS34.SA": {
        "short_name": "THERMFISCHERDRN",
        "long_name": "Thermo Fisher Scientific Inc.",
        "summary": "Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems and antibody tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; cancer diagnosis and medical research products; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, and ultralow-temperature freezers and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics and chemicals; and pharma services. It has collaboration with WuXi Diagnostics and Mayo Clinic to develop antibodies tests; a strategic collaboration with Schr\u00c3\u00b6dinger, Inc.; an agreement with Daiichi Sankyo; collaboration with Northeastern University; and partnership with Boys & Girls Clubs of America. The company was incorporated in 1956 and is headquartered in Waltham, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Waltham"
    },
    "TRBA.F": {
        "short_name": "TRINITY BIOTEC.ADR NEW A",
        "long_name": "Trinity Biotech plc",
        "summary": "Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Ireland",
        "city": "Bray"
    },
    "TRIB": {
        "short_name": "Trinity Biotech plc",
        "long_name": "Trinity Biotech plc",
        "summary": "Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Ireland",
        "city": "Bray"
    },
    "TTOO": {
        "short_name": "T2 Biosystems, Inc.",
        "long_name": "T2 Biosystems, Inc.",
        "summary": "T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "TWST": {
        "short_name": "Twist Bioscience Corporation",
        "long_name": "Twist Bioscience Corporation",
        "summary": "Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "U4W.F": {
        "short_name": "QUOTIENT LTD",
        "long_name": "Quotient Limited",
        "summary": "Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "city": "Eysins"
    },
    "VIMTALABS.NS": {
        "short_name": "VIMTA LABORATORIES",
        "long_name": "Vimta Labs Limited",
        "summary": "Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers laboratory, food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. It serves the pharmaceutical, biopharmaceutical, food, consumer products, agrochemical, healthcare, medical device, and other industries. The company was founded in 1984 and is headquartered in Hyderabad, India.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Hyderabad"
    },
    "VIVO": {
        "short_name": "Meridian Bioscience Inc.",
        "long_name": "Meridian Bioscience, Inc.",
        "summary": "Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cincinnati"
    },
    "VNRX": {
        "short_name": "VolitionRX Limited",
        "long_name": "VolitionRx Limited",
        "summary": "VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRx Limited is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "VRCI.L": {
        "short_name": "VERICI DX PLC ORD GBP0.001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Penarth"
    },
    "VRTT": {
        "short_name": "VIATAR CTC SOLUTIONS INC",
        "long_name": "Viatar CTC Solutions Inc.",
        "summary": "Viatar CTC Solutions Inc., a biotechnology company, focuses on developing and marketing cancer molecular diagnostics and cancer therapy products in the United States. Its products include Viatar collection system for molecular analysis that collects and purifies circulating tumor cells (CTCs) for DNA sequencing and other genetic analysis technologies used primarily for research; and Viatar therapeutic oncopheresis system to remove CTCs from a patient's blood as a new cancer therapy for metastatic disease. The company was formerly known as Vizio Medical Devices LLC and changed its name to Viatar CTC Solutions Inc. in February 2014. Viatar CTC Solutions Inc. was founded in 2007 and is headquartered in Lowell, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Lowell"
    },
    "WAT": {
        "short_name": "Waters Corporation",
        "long_name": "Waters Corporation",
        "summary": "Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Milford"
    },
    "WAZ.F": {
        "short_name": "WATERS CORP.  DL-,01",
        "long_name": "Waters Corporation",
        "summary": "Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Milford"
    },
    "WFL.AX": {
        "short_name": "WELLFULLYL FPO",
        "long_name": "Wellfully Limited",
        "summary": "Wellfully Limited develops dermaportation and enhanced transdermal polymer technologies for use in the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors in Australia. The company provides partnering services and product solutions for technologies in transdermal and intra-dermal drug delivery; therapeutic and dermatological skincare; cosmetic and non-medicinal active ingredient; oral health; haircare solutions utilizing enhanced brushes and applicators; high penetration surface hygiene technologies; fabric and carpet cleaning technologies; and industrial surface interface systems. It offers various technology platforms, such as Static Micro-arrays, a film based micro-array technology for patches, masks, dressings, and other topical applications; and Field in Motion Micro-arrays, a magnetic micro-array film for use in brushes, applicators, and wipes; Dermaportation, a product development platform for a range of commercial applications; eSkin, a multi-product delivery system that offers a range of product-specific, time-varying magnetic fields for enhanced delivery of multiple formulations; and measured dose delivery devices and packaging solutions. The company was formerly known as OBJ Limited and changed its name to Wellfully Limited in September 2020. Wellfully Limited was founded in 2004 and is based in Leederville, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Leederville"
    },
    "WUXIF": {
        "short_name": "WUXI APPTEC CO LTD",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd. provides research and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through, China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CMO/CDMO Services, and Other segments. It offers pharmaceutical discovery services across the drug discovery process; laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CMO/CDMO services; and administrative services, as well as sells scrap materials. The company was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Shanghai"
    },
    "WX8.F": {
        "short_name": "WUXI APPTEC H 02359 YC1",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd. provides research and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through, China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CMO/CDMO Services, and Other segments. It offers pharmaceutical discovery services across the drug discovery process; laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CMO/CDMO services; and administrative services, as well as sells scrap materials. The company was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Shanghai"
    },
    "XCY.F": {
        "short_name": "OPKO HEALTH INC.  DL-,01",
        "long_name": "OPKO Health, Inc.",
        "summary": "OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Miami"
    },
    "XGN": {
        "short_name": "Exagen Inc.",
        "long_name": "Exagen Inc.",
        "summary": "Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Vista"
    },
    "XSQ.F": {
        "short_name": "SQI DIAGNOSTICS INC.",
        "long_name": "SQI Diagnostics Inc.",
        "summary": "SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for multiplexing diagnostics in Canada. It offers a range of multiplexed products and services, including detecting and quantifying proteins, antibodies, and DNA. The company provides sqidworks, a workhorse system that enables to load plates and get report; sqidlite, a benchtop system, which allows processing one plate per run; and sqid-X that accesses various multiplexing power of Ig_plex technology with its semi-automated system. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. The company serves pharmaceutical and biotechnology drug development, human diagnostic testing, and animal health diagnostic testing markets. SQI Diagnostics Inc. was founded in 1999 and is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "YGEN.L": {
        "short_name": "YOURGENE HEALTH PLC ORD 0.1P",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Manchester"
    }
}